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Aco1: Aconitase 1 
Aco2: Aconitase 2 
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cAMP: Cyclic Adenosine Mono Phosphate 
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CREB: cAMP Response Element-Binding protein 
CV: Complex V / ATP Synthase 
DAPI: 4′,6-diamidino-2-phenylindole 
dbcAMP: Dibutyryl Cyclic Adenosine Monophosphate / Bucladesine 
DMEM: Dulbecco’s Modified Eagle Medium 
DMSO: Dimethyl Sulfoxide 
DNA: Deoxyribonucleic Acid 
DTT: Dithiothreitol 
ECL: Enhanced ChemiLuminescence 
EDTA: Ethylene Diamine Tetraacetic Acid 
EGF: Epidermal Growth Factor 




ETR: Electron Transport Chain 
FBS: Fetal Bovine Serum 
FCCP: Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone 
FNDC5: Fibronectin Type III Domain Containing 5 
FRDA: Friedreich’s Ataxia 
FXN: Frataxin 
GABA: γ-AminoButyric Acid 
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase 
GDNF: Glial-cell Derived Neurotrophic Factor 
GFP: Green Fluorescent Protein 
HBSP: Helix B Small Peptide 
HBSS: Hank’s Balanced Salt Solution 
HEK 293T: Human Embryonic Kidney 293 cells with SV40 large antigen 
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HDAC: Hystone Deacetylase 
hrFGF: Human Recombinant Fibroblast Growth Factor 
IDH: Isocitrate Dehydrogenase 
IDLVs: Integration-Deficient Lentiviral Vectors 
IL-6: Interleukin-6 
INFγ : Interferon-γ 
iPS: Induced Pluripotent Stem cells 
IREs: Iron Responsive Elements 
ISCs: Iron-Sulfur Clusters 
ISCU: Iron-Sulfur Cluster assembly enzyme 
MOI: Multiplicity of Infection 
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MIP-1α : Macrophage Inflammatory Protein-1α 
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MPP: Mitochondrial Processing Peptidase 
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MTT: 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide 
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NEAA: Non-Essential Amino Acids 
NGF: Nerve Growth Factor 
NK: Natural Killer cells 
NMDAR: N-Methyl-D-Aspartate Receptor 
NRF: Nuclear Respiratory Factor 
NT-3: Neurotrophin-3 
OCR: Oxygen Consumption Rate 
OMScs: Olfactory Mesenchymal Stem cells 
PARP: Poly ADP-Ribose Polymerase 
PBS: Phosphate Saline Buffer 
PCR: Polymerase Chain Reaction 
PFA: Paraformaldehyde 
PGC-1alpha: Peroxisome Proliferator-Activated Receptor Gamma Coactivator - 1alpha 
PMS: Phenazine Methosulfate 
PPAR-γ: Peroxisome Proliferator-Activated Receptor gamma 
qPCR: Quantitative Polymerase Chain Reaction 
qRT-PCR: Quantitative Retro Transcribed Polymerase Chain Reaction 
ROS: Reactive Oxygen Species 
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SCF: Stem Cell Factor 
SDS: Sodium Dodecyl Sulfate 
SHH: Sonic Hedgehog 
STAT: Signal Transducer and Activator of Transcription 
TFAM: Mitochondrial Transcriptional Factor A 
TGF-β: Transforming Growth Factor β 
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Friedreich’s Ataxia (FRDA) is a mainly neurodegenerative recessive disease caused by the 
deficiency of frataxin protein. This deficiency is mostly due to the expansion of the GAA triplet 
located in the first intron of frataxin gene. This mutation leads to the reduction in the levels of the 
protein, which fall around 20-30% of normal levels. Frataxin, in its canonical mature form, is a 
protein localized to the mitochondria, where it exerts its roles, mostly involved in iron storage, in 
the formation and regulation of Iron-Sulfur clusters and in maintaining mitochondrial 
homeostasis. 
Recently the existence of different isoforms of frataxin with an extra-mitochondrial 
localization has been indicated. We found that the overexpression of both mitochondrial isoform 
I and cytosolic isoform II is able to improve mitochondrial respiration in FRDA patient cells, 
increasing basal respiration rates and oxygen consumption rates and incrementing the levels of 
mitochondrial biomarkers like VDAC and Aconitase. Besides, the overexpression of canonical 
Isoform I is directly affecting the development of mitochondrial network, exerting a positive 
effect on both the number of isolated mitochondria as well as the number of mitochondria 
structured in networks. Finally, both isoforms seem to interact with Fe-S cluster containing 
proteins, like cytosolic and mitochondrial Aconitase, being also able to protect the enzymes in an 
oxidative-stressing environment. 
The regulation of frataxin gene expression is another issue of major interest for its possible 
therapeutic relevance.  Several factors including Erythropoietin and some Epo-mimetic molecules 
have been reported to increase frataxin levels. There are some drawbacks, since canonical Epo 
can cause hematocrit problems, while some of the derivative peptides described are known to be 
highly unstable, with a very low half-life in the organism. For this reason, we decided to focus on 
a retro-enantiomeric version of a HBSP-based peptide, called EPO2. We described in this work 
the positive regulatory effects on frataxin of this synthetic epomimetic peptide, both in vitro in 
several cell models and in vivo in the cerebellum of wild type mice.  
Finally, we reported the effects of spontaneous physical activity in wild type mouse 
cerebellum on frataxin expression. Frataxin levels appeared positively modulated after exercise, 
suggesting a post-transcriptional regulation mechanism. We investigated for possible mediators 
of this beneficial effect by qPCRs and through a cytokine array which highlighted the 
upregulation of several factors, including the neurotrophin NT-3, SHH protein, MIP-1α and IFN-
γ, pointing the way to a multi-layered regulatory complex behind frataxin modulation set up by 
physical exercise.  
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Together, these results give more insight on part of the mechanisms underlying frataxin 
regulation, which could prove useful in the development of potential new strategies in the 





La Ataxía de Friedreich (FRDA) es una enfermedad predominantemente 
neurodegenerativa causada por la deficiencia de la proteína Frataxina. Esta deficiencia es 
mayormente debida a la expansión del triplete GAA localizado en el primer intrón del gen de la 
frataxina, la cual es responsable de la reducción de los niveles de la proteína, que se sitúan 
alrededor de un 20-30% de los niveles normales. La frataxina, en su forma canónica madura, es 
una proteína mitocondrial involucrada en el almacenamiento de hierro, la formación y regulación 
de centros hierro-azufre y el mantenimiento de una correcta homeostasis mitocondrial.  
Estudios recientes han observado la existencia de diferentes isoformas de frataxina de 
localización extra-mitocondrial. En este trabajo hemos demostrado que la sobreexpresión de 
ambas isoformas de frataxina, la isoforma I mitocondrial y la isoforma II citosólica, es capaz de 
mejorar la respiración mitocondrial en células de paciente de FRDA, incrementando los niveles 
de respiración basal y la tasa de consumo de oxígeno, aumentando, también, el nivel de 
biomarcadores mitocondriales como por ejemplo VDAC y Aconitasa. Además, la sobreexpresión 
de la isoforma I es directamente responsable de inducir una mejora en el desarrollo de la red 
mitocondrial, ejerciendo un efecto positivo en el aumento de mitocondrias aisladas y en el número 
de mitocondrias estructuradas en red. Finalmente, ambas isoformas parecen interactuar con los 
centros Fe-S contenidos en las proteínas, como por ejemplo de la aconitasa mitocondrial y la 
citosólica, y además protegen a estas enzimas en condiciones de estrés oxidativo. 
La regulación de la expresión del gen de la frataxina es otro tema de gran interés por su 
posible relevancia terapéutica. Se ha visto que varios factores son capaces de incrementar los 
niveles de frataxina, entre los cuales figuran la Eritropoyetina y algunas moléculas Epo-
mimeticas. Existen algunos inconvenientes debido al hecho de que el péptido Epo canónico puede 
provocar problemas en el hematocrito, mientras que algunos de los análogos descritos parecen 
ser altamente inestables, con una vida media en el organismo muy corta. Por estas razones, hemos 
decidido enfocarnos en una versión retro-enantiomérica de un péptido basado en HBSP, llamado 
EPO2. Hemos descrito en este trabajo los efectos positivos de este péptido epomimetico sobre la 
expresión de frataxina, in vitro en distintos modelos celulares e in vivo en el cerebelo de ratones 
wild-type.  
Finalmente, hemos observado los efectos de la actividad física espontánea sobre los 
niveles de frataxina en el cerebelo de ratones wild-type. Estos niveles parecen estar modulados 
positivamente después del ejercicio, y nuestros resultados sugieren un mecanismo de regulación 
post-transcriptional. Hemos estudiado los posibles mediadores de este efecto beneficioso 
mediante qPCR y a través de un array de citoquinas, permitiéndonos identificar el aumento de 
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distintos factores, incluyendo la neurotrofina NT-3, la proteína SHH, MIP-1α y IFN-γ, lo cual 
indica un complejo mecanismo regulatorio detrás del aumento de los niveles de frataxina inducido 
por el ejercicio físico. 
En conjunto, estos resultados nos han permitido profundizar en una parte de los 
mecanismos que subyacen a la regulación de frataxina, lo cual podría ser de gran utilidad para el 






1. Friedreich’s Ataxia: 
Friedreich’s Ataxia (FRDA) is an inherited autosomal recessive disease described for the first 
time by Dr. Nikolaus Friedreich in 1863. It belongs to a group of rare neurological disorders called 
Autosomal Recessive Cerebellar Ataxias (ARCAs) which are characterized by a degeneration 
and/or a defective development of the spinocerebellar system. FRDA is the less “rare” of the 
ataxias, affecting roughly 1-2 every 50000 Caucasians.  
Being an ataxia, it is characterized by the lack of motor coordination; the development of the 
disease is slow, but steady during the lifespan of an individual, with the first symptoms starting 
to show themselves during childhood. Not all the symptoms show at the same time, but often the 
earliest ones include poor articulation of phonemes (dysarthria), blurred vision (diplopia), 
difficulties in swallowing (dysphagia), uncontrolled movements of the eyes (nystagmus), 
abnormal reflexes of lower extremities (Babinsky response), and loss of proprioception. In 
addition to neurological symptoms, a high number of patients also show extra-neurological signs, 
as mitochondrial energy production deficit in muscle (Lodi, Cooper et al. 1999), skeletal 
abnormalities such as scoliosis and pes cavus (Parkinson, Boesch et al. 2013), type II diabetes 
(Cnop, Mulder et al. 2013), glucose intolerance (Finocchiaro, Baio et al. 1988) and hypertrophic 
cardiomyopathy (Regner, Lagedrost et al. 2012). 
Even though the disease has always been described as an early onset neurodegenerative 
disease, recent findings indicate that it is possibly composed by two “steps”: a developmental 
hypoplasia mainly affecting the spinal cord and medulla, and a neurodegenerative process mainly 
affecting the cerebellum. Thus, the patients are born with a neuronal deficiency in the spinal cord 
and medulla and with normal cerebellar nuclei, which are bound to slowly neurodegenerate over 
time (Mascalchi, Toschi et al. 2016). Neuropathologic and imaging studies show that the 
development of the disease begins with an atrophy of spinal ganglia, spinal cord and of the 
medulla oblongata, followed by a neurodegenerative process of the cerebellum with a focus on 
the deep nuclei (especially the dentate nucleus) where a degeneration of the glutamatergic neurons 
and of the corticonuclear synaptic terminals containing γ-aminobutyric acid (GABA) takes place. 
In later stages of the disease, other areas affected are represented by cerebellar vermis and cortex 
(Koeppen and Mazurkiewicz 2013). Furthermore, recent findings indicate there is a direct glial 
cells contribution during FRDA development, shown both in Drosophila (Navarro, Ohmann et al. 
2010) and by our group in human astrocytes (Loria and Diaz-Nido 2015). These results have been 
further confirmed by analyzing plasma levels, in FRDA patients, of glial markers such as the Glial 
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Fibrillary Acidic Protein (GFAP), along other factors indicating neuronal damage such as the 
Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1) and the Neurofilament-Light Chain (NfL), 
which could be used as potential biomarkers to achieve a better understanding of disease 
progression (Zeitlberger, Thomas-Black et al. 2018). 
 
 Molecular bases of FRDA: 
Friedreich’s ataxia originates from mutations in FRDA gene, located at the chromosome 9p13 
(Chamberlain, Shaw et al. 1988; Campuzano, Montermini et al. 1996). This gene, also known as 
X25, encodes for frataxin (FXN) protein, a ubiquitous protein, mostly localized in mitochondria. 
X25 gene is composed by 7 exons (Baralle, Pastor et al. 2008) spanning around 80kb, but only 
the first five exons are responsible of codifying for FXN protein. The most common mutation in 
FRDA patients is the expansion of the GAA (guanine-adenine-adenine) triplet contained in the 
first intron of the gene (Campuzano, Montermini et al. 1996; Cossee, Schmitt et al. 1997): a 
certain number of GAA repeats is present even in non-patients, with up to 60-70 GAA repeats 




The GAA expansion is the major cause of the disease, being present in homozygosis in 95% 
of patients, while the rest are commonly compound heterozygous for the expansion and a point 
mutation (De Castro, Garcia-Planells et al. 2000). Up to 30 point mutations have been identified, 
including both missense and nonsense mutations, giving rise to either anomalous or truncated 
versions of FXN protein. No homozygous patients with point-mutations have been identified 
(Galea, Huq et al. 2016). 
 
Figure 1 - Effects of GAA repeats on Frataxin levels. GAA expansion induces heterochromatin domains which 
ultimately lead to reduced levels of the protein 
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The GAA triplet expansion causes a significant reduction in transcription levels, with 
mechanisms not yet fully established and still controversial. One possible cause could be the 
induction of “sticky DNA” aberrant structures that could physically block the RNA polymerase 
II, thus hindering its movement along the DNA template (Sakamoto, Ohshima et al. 2001). 
Another mechanism hypothesized involves the formation at the GAA expansion of aberrant 
DNA/RNA hybrid structures, called R-loops, that could ultimately lead to an aberrant termination 
of transcription (Butler and Napierala 2015). This reduction in transcription levels would be also 
followed by a gradual heterochromatization of FXN gene (Kumari and Usdin 2012). Previous 
studies showed that FRDA patients actually do possess a very condensed chromatin, due to the 
deacetylation and hypermethylation of histones, so GAA repeats could provoke both phenomena 
at the same time: a reduction in transcription rates and the induction of heterochromatin domains 
(Yandim, Natisvili et al. 2013). 
There are evidences of a direct correlation between the number of GAA repeats and the 
amount of protein: the higher the number of repeats, the lower the amount of frataxin. Therefore, 
even another conclusion can be drawn: the higher the number of repeats, the sooner the symptoms 
are bound to appear, and this applies also to the intensity of such symptoms (Evans-Galea, 
Carrodus et al. 2012) 
 
2. Frataxin: structure and functions 
Frataxin is a ubiquitous protein with major abundance in tissues in which there is a high 
energetic demand, such as brain, heart, liver, pancreas and spinal cord. In its canonical mature 
form, frataxin localizes inside the mitochondria (Campuzano, Montermini et al. 1997), associated 
with the inner membrane. It is synthesized as a precursor protein (210aa, 23kDa) that is then 
processed, cleaved and sent to the mitochondria, process mediated by the mitochondrial targeting 
sequence (MTS) that the precursor possesses on the N-terminal domain. The protein complex 
responsible of the precursor processing is the mitochondrial processing peptidase (MPP) that 
cleaves the precursor producing an intermediate form (42-210, 19 kDa) that is then further 
processed to free the mature form of frataxin (81-210, 14,2 kDa). The molar ratio between these 
two forms is thought to be modulable, with FRDA patients shifting towards a faster conversion 
of the 42-210 form into the 81-210 one. Furthermore, the 42-210 form exists in mono- and 
oligomeric configurations, similarly to several components of the Fe-S cluster assembly 
machinery (Gakh, Bedekovics et al. 2010) 
Over the course of time, there have been described many alternative forms of frataxin protein 
(or isoforms): the first ones have been described by Campuzano (Campuzano, Montermini et al. 
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1997) originated though an alternative splicing event in intron 4; another one has been described 
by Pianese (Pianese, Tammaro et al. 2002) containing exon 5b and not 5a. 
 Recently, another group (Xia, Cao et al. 2012) described even more isoforms with different 
cellular localization and tissue distribution. These new isoforms are called FXN II and FXN III 
(Fig.2): in both of them the MTS is absent, so they are not localized in the mitochondria. FXN II 
is transcribed from a different starting point and possess a different first exon (Exon 1b /∆18), 
while FXN III is obtained through an alternative splicing of exon 1a (exon 1a, ∆141).  
 
 
According to the work of Xia et al., these isoforms seem to be tissue-specific, with the Isoform 
II localized mainly in the cerebellum and Isoform III mostly abundant in heart. Furthermore, their 
cellular distributions seem to be different too, with the II being cytosolic and the III being nuclear. 
Isoform II might be involved in protecting iron-sulfur clusters (ISCs) from oxidative damage, 
while Isoform III might activate the biogenesis of mitochondrial ISCs, according to the 
description provided by Xia. Previous work from our laboratory has demonstrated that by 
delivering the whole 135kb FXN genomic locus to FRDA patient cells, all the isoforms are 
detectable in cells from healthy subjects and patients (Perez-Luz, Gimenez-Cassina et al. 2015). 
As for frataxin functions, several hypotheses are postulated on the important cellular 
functions in which frataxin play a role (Fig.3):  
It is thought that frataxin is capable to bind iron and regulate its storage inside the 
mitochondria (Isaya, O'Neill et al. 2004), by forming a complex which can accumulate many iron 
atoms (Fig 3 – a). Frataxin is also involved in protecting iron from oxidation that could occur 
inside the mitochondria and to supply it to other proteins (Adamec, Rusnak et al. 2000; Gakh, 
Adamec et al. 2002), such as the ferrochelatase (heme synthesis, Fig. 3 - b) (Bencze, Yoon et al. 
2007). Other potential targets of the iron transferring include the Iron-Sulfur Cluster assembly 
enzyme (ISCU) and Cysteine desulfurase NFS1 (encoded by NSF1 gene), involved in the 
formation of Iron-Sulfur Clusters (ISCs).  
In addition, frataxin itself participates in ISCs formation directly, by stabilizing the ternary 
complex of ISCU/NFS1/ISD11 (Fig 3 – c), otherwise the ternary complex would not be correctly 
Figure 2 - Diagram showing differences between Frataxin isoforms (I, II and III in order) following Xia et al. results 
25 
 
formed, and it would be unable to transfer Fe-S clusters to other proteins (Colin, Martelli et al. 
2013). Furthermore, also the 42-210 oligomeric form of frataxin has been shown to possess the 
ability of forming stable complexes with NFS1/ISD11, which could act as a backup Fe-S cluster 
formation mechanism under the appropriate metabolic activation switch (Gakh, Bedekovics et al. 
2010). 
Apart from participating in the ISCs formation, Frataxin is also probably involved in the 
repair of ISCs (such as the one of mitochondrial aconitase) by protecting them from the prooxidant 
action and maintaining them in the [4Fe-4S]2+ active form (Fig 3 – d), (Bulteau, O'Neill et al. 
2004). 
Another postulated function is the possible interaction of Frataxin with components of the 
electron transport chain, in particular with the succinate dehydrogenase (Complex II, Fig 3 - e) 
(Gonzalez-Cabo, Vazquez-Manrique et al. 2005), thus increasing electron transport and oxidative 
phosphorylation itself. 
Last, Frataxin may participate in the antioxidant response of cells in conjunction with the 
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-alpha) (Marmolino 
2011) and the nuclear factor-E2-related factor-2 (Nrf2) (Shan, Schoenfeld et al. 2013), both 
downregulated in FRDA cells (Fig 3 – f). 
Even though there still is some debate on the exact roles performed by Frataxin, it is clear 
that all of these functions are part of the same net and that frataxin deficiency leads to an 
deregulated iron metabolism and to defective ISCs which, in turn, mean that iron could react with 
reactive oxygen species (ROS) in order to produce further damage in the mitochondria and, thus, 
in the whole cell.  
ISCs are key elements of several cellular metabolic pathways and are needed to maintain 
correct homeostasis, in practically all living organism, from archaea to eukaryotes. Many enzymes 
involved in nucleic acid, amino acid and lipid metabolism or DNA repair machinery contain iron-
sulfur clusters, thus marking the importance of these cofactors (Fontecave 2006). For this reason, 
their assembly is strictly regulated by cells with a complex controlled system involving many 
partners, including 18 mitochondrial cluster assembly proteins (ISC) and 11 cytosolic assembly 
proteins (CIA), underlying the existence of different isoforms of the ISCs assembly machinery 
distributed in different cellular compartments (Rouault and Maio 2017). The postulated assembly 
process involves the synthesis of a de novo [2Fe-2S] cluster by an early-acting ISC machinery. 
This cluster is then processed by a late-acting machinery to produce the functional [4Fe-4S] 
clusters which are either transported to the corresponding mitochondrial target apoproteins or 
exported to the cytosol to be assembled to cytosolic targets by the CIA machinery (Braymer and 
Lill 2017). Finally, frataxin is thought to have a role on ISCs formation process, by acting as a 
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metabolic switch by determining the allocation, in mitochondria, of iron used for ISCs synthesis 
(Chiang, Kovacevic et al. 2016) 
 
As for the different isoforms, they are thought to be involved in protecting ISCs from 
oxidative damage (Iso II) and activating ISCs biogenesis (Iso III) (Xia, Cao et al. 2012); however, 
their precise function has not yet been fully described yet. Precisely, further developments in these 




















Figure 3 - Diagram showing Frataxin postulated functions. a) Iron binding and storage, b) Iron donor to Ferrochelatase 
during Heme biosynthesis, c) Iron donor and physical stabilizer of the ISCU/NSF1/ISD11 complex during ISCs 
biosynthesis, d) Transfer and reparation of ISCs to recipient proteins, e) Interaction with Succinate Dehydrogenase 




3. Frataxin in mitochondrial metabolism and biogenesis 
Being frataxin a mitochondrial protein involved in all the functions we have previously 
unraveled and with such a strong impact on this organelle, it is clear that mitochondrial biogenesis 
and metabolism study is a key factor for FRDA research. Starting from organisms like C. elegans 
and yeast, frataxin deficiency leads to impairments in components of the OXPHOS (Complex II, 
in particular, following the work of Gonzalez-Cabo (Gonzalez-Cabo, Vazquez-Manrique et al. 
2005). Moving up the evolutionary ladder, it is known that, in myocardial tissue and blood from 
patients, the OXPHOS is impaired and that they show abnormalities in complex I, II and III 
(Rotig, de Lonlay et al. 1997) (Salehi, Kamalidehghan et al. 2014), but little is known about the 
most affected tissues like brain and cerebellum. Recent studies in frataxin-deficient mouse (see 
section 4) cerebellum have shown that PGC-1α which is involved in mitochondrial biogenesis, is 
strongly downregulated compared to its levels in WT mice both at asymptomatic (P30, 60, 90) 
and at symptomatic (P270) ages, suggesting an early impairment of PGC-1α and its mitochondrial 
biogenetic roles. These findings were also confirmed for the factors downstream of PGC-1α, such 
as the Nuclear Respiratory Factor 1 (NRF1) and the Mitochondrial Transcriptional Factor A 
(TFAM or mtTFA) suggesting that the PGC1α/TFAM/NRF1 mitochondrial biogenesis pathway 
in the cerebellum of these mice is strongly impaired which could lead to the dysfunction typical 
of FRDA. Moreover, even the function of the subunits of the respiratory complex is compromised, 
with the activity of Complex I, II and IV significantly diminished in the cerebellum of KIKO mice 
(Lin, Magrane et al. 2017). Similar findings were also confirmed in KIKO brain tissue, but, more 
importantly, in patient fibroblasts and whole blood (Jasoliya, McMackin et al. 2017), thus 
correlating the decreased mitochondrial biogenesis with low frataxin expression and suggesting 
mitochondrial biogenesis as a FRDA biomarker. 
Interestingly, Jasoliya also showed that overexpression of canonical frataxin is directly 
related to the increment of Voltage-Dependent Anion Channel (VDAC) protein, confirming the 
direct effect of frataxin upon mitochondrial biogenesis. In this picture, unknown are the functions 
of the cytosolic frataxin isoform II which could be involved in preserving iron homeostasis, and 
thus mitochondrial correct functioning, “from the outside” of the mitochondria itself: in cytosol. 
We have already said that the canonical isoform of frataxin is involved in stabilizing the iron-
sulfur cluster of mitochondrial aconitase (Aco2), but it is also known that there is another, 
cytosolic, form of Aconitase (Aco1 or IREB1) which has shown moonlight activity: when 
intracellular iron levels are low, Aco1 binds to Iron Responsive Elements (IREs) located on the 
mRNAs of ferritin (thus inhibiting its translation, being ferritin involved in iron storage) and of 
transferrin (involved in iron import from the outside of the cell), stabilizing its mRNA. When 
intracellular iron levels are not low anymore, the protein becomes a fully-fledged aconitase, 
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incorporating an iron sulfur cluster and restoring the balance between ferritin and transferrin 
(Seznec, Simon et al. 2005). 
 
4. FRDA: Experimental models 
Cellular and animal models that allow for a better understanding of the processes happening 
during FRDA development, are mandatory for unraveling the biological functions of frataxin and 
its isoforms as well as to permit the discovery of potential new therapeutic approaches. Being 
frataxin a phylogenetically highly conserved protein, over the years a high number of different 
models, cellular or animal, have been characterized, which allows for a better view of the 
mechanisms underlying the disease. Unicellular models like E. coli or S. cerevisiae have the credit 
to have allowed for the characterization of frataxin and its functions and have been fundamental 
in opening the way for more “complex” systems reproducing the more characteristic aspects of 
the disease: between these models, the most useful has been the yeast Saccharomyces cerevisiae, 
due the discovery of the analogue gene Yeast Frataxin Homolog 1 (YFH1). It was, then, possible 
to create a strain expressing no YFH1 thus seeing features similar to the ones observed in patients: 
impaired oxidative phosphorylation, iron accumulation and a higher sensitivity to oxidative stress 
(Foury and Cazzalini 1997).  
 
In the following table, some of the models used in literature can be found: 
 
Model Features Reference 
Unicellular Models 
E. coli 
Deletion of the homologous Fxn gene does not 
provoke iron accumulation or oxidative stress. 
(Li, Ohshima 
et al. 1999) 
Saccharomyces 
cerevisiae 
Deletion of the homologous Fxn gene causes 
iron accumulation, impaired OXPHOS and 






Silencing Fxn induces increased sensitivity to 










Fxn silencing induces ISCs and Heme 
formation deficiency, aconitase activity 
reduction, increased sensitivity to oxidative 
stress and an overall reduced life span. 
(Anderson, 
Kirby et al. 
2005; 
Navarro, 
Ohmann et al. 
2010; Calap-
Quintana, 
Navarro et al. 
2018) 
 
Neural cell Models 
SH-SY5Y 
FXN silencing through shRNA provokes 
mitochondrial dysfunctions, higher oxidative 




Molla et al. 
2014) 
(Palomo, 
Cerrato et al. 
2011) 
Astrocytes 
FXN silencing causes altered mitochondrial 
morphology and higher sensitivity to oxidative 






FXN silencing induces activation of 
inflammatory pathways and apoptotic genes, 





cultures of rat 
DRG neurons 
Frataxin depletion caused mitochondrial 
membrane potential decrease, neurite 
degeneration, altered calcium homeostasis and 
apoptosis.   
(Mincheva-
Tasheva, Obis 





Frataxin depletion induced activation of 
Caspase-3 and caused apoptotic cell death. (Katsu-
Jimenez, Loria 
et al. 2016) 
Models derived from FRDA patients 
Lymphocytes 
Increased sensitivity to oxidative damage, ISCs 
proteins deficiency. 
(Rotig, de 







Table 1 – Principal models that are used in FRDA research 
 
In the table, for mammalian cell models, only models of neural lineage are shown. The most 
appropriate and “physiological” cell models are, clearly, the ones deriving from patients, 
containing the GAA expansion along with the complete frataxin locus. Unfortunately, the most 
common patient cell models used in FRDA research are not of neural lineage and this is why, 
more recently, fibroblasts are being reprogrammed into induced pluripotent stem cells (iPS) and 
then into neurons or, directly into neurons (iN cells) in order to have a more disease-relevant cell 
model to investigate. Hick et al. have shown that iPS differentiated into neurons maintain low 
frataxin levels and have proper morphology, but possess a weak biochemical phenotype compared 
to patient cells. This makes this model an optimal one to study potential therapies focused on 
rising frataxin levels, but probably it would be best to use another one to study the molecular 
mechanisms triggered by frataxin deficiency. 
Apart from cellular in vitro models, animal models have a big impact on FRDA research, 
allowing to study in vivo the effects of frataxin deficiency. We have to say that a complete frataxin 
knockout is lethal and unviable (Cossee, Puccio et al. 2000), so, at first, conditional models in 
Fibroblasts 
Increased sensitivity to oxidative damage, ISCs 
proteins deficiency. 
(Sturm, 








Donze et al. 
2013) 
Mammalian Animal Models 
KIKI 
Knock-in in homozygosis with ~126 GAA 
repeats. Approximately 70% of fxn levels 
compared to healthy mice. 
(Miranda, 
Santos et al. 
2002) 
KIKO 
Knock-in with ~230 repeats and knock-out on 
the other allele. Around 30% of fxn levels 
compared to healthy mice. 
(Miranda, 
Santos et al. 
2002) 
YG8R 
Murine frataxin delete with a YAC expressing 
human fxn containing GAA expansion. Mild 
phenotype. 
(Al-Mahdawi, 
Pinto et al. 
2006) 
YG8sR 
Like YG8R, but with more GAA repeats and a 







which frataxin could be silenced from the tissue of interest via Cre recombinase, leading to a 
severe phenotype, even harsher than the one seen in patients, since FRDA is developed slowly 
and gradually over the years. That is why other mouse models have been developed, for example 
the KIKI/KIKO in which there is a double or single knock-in of the GAA expansion in the murine 
frataxin gene (Miranda, Santos et al. 2002) or the YG8R/sR in which murine frataxin has been 
replaced with a single copy of human frataxin containing the GAA expansion. The “sR” version 
of this model, includes a contracted version of human frataxin with more repeats, giving a stronger 
phenotype compared to the YG8R version. Recently, another model is being characterized, called 
YG8LR (not yet available for purchase) containing even more repeats than the sR and resulting, 
in general, more stable as a model (M. Pook, personal communication). 
 
5. Regulation of frataxin expression 
After a brief overview of FRDA and the status of its research, it appears clear that Frataxin is 
involved in so many processes of the utmost importance for the cell and its physiology. For this 
reason, we decided to focus this thesis on its regulation, being it a field with many aspects yet to 
clarify. Frataxin regulation is a multi-layered area in which a network of various factors is taking 
part. We decided to point our attention on several “sub-fields” in several of the models we 
examined earlier, with the goal of reaching a better understanding on frataxin expression 
mechanisms which could be useful in gaining new knowledge on FRDA itself and, hopefully, in 
the design of potential new treatments. 
 
 Frataxin isoforms 
Little is known about frataxin isoforms which have been recently described by Xia (Xia, Cao 
et al. 2012). Aside from what we have described before, the three isoforms only differ in the first 
exon, while exon 2, 3, 4 and 5 are the same for the three of them (Fig.1). In this work we have 
tried to characterize these isoforms, evaluating their localization inside the cell and trying to gain 
insight into the functions they could be involved into. In order to do this, we have used lentiviral 
vectors carrying the sequence codifying for the different isoforms to transduce the cells and study, 






 Erythropoietin-derived peptides 
As mentioned earlier in this introduction, one of the approaches for FRDA treatment consists 
of using recombinant human erythropoietin-derived peptides which are able to elicit a 
neuroprotective effect and, specifically, to increment frataxin levels binding to an alternative EPO 
receptor (Brines and Cerami 2005; Siren, Fasshauer et al. 2009; Miller, Rai et al. 2017), apart 
from the classical one. Erythropoietin has been known as a modulator of erythropoiesis and, as 
such, was shown to produce some side-effects like an increment in hematocrit which, 
unfortunately, represents a serious obstacle in the clinical use of EPO as a therapeutic drug for 
the treatment of patients. Studies with recombinant-human EPO in lymphocytes and cardiac 
myoblasts from FRDA patients, demonstrated that the peptide is able to induce increments in 
frataxin protein levels up to 2.5 fold in a dose-dependent manner: this increase can be observed 
just after a few hours after the treatments. Previous work from our lab has shown that alternative 
forms of erythropoietin, such as the carbamylated form (CEPO) and a synthetic peptide produced 
from the aminoacids composing the soluble part of the B-Helix of EPO (Helix B Small Peptide, 
HBSP) are able to produce an increment in frataxin protein levels in neuroblastoma SH-SY5Y 
cells (both in proliferation or differentiated in “neuron-like” cells) and in olfactory mesenchymal 
stem cells from FRDA patients (Thesis Yurika Katsu-Jiménez, 2013). Based on these results, 
even more studies are currently ongoing using these peptides or synthetic derivatives with several 
advantages, which has been one of the focuses of this work and has been debated extensively in 
later parts of this thesis. It must be noted that while both rhEPO and the carbamylated form CEPO 
have reached the stage of clinical trial (Sacca, Piro et al. 2011; Mariotti, Fancellu et al. 2012; 
Boesch, Nachbauer et al. 2014), few data are available in animal models: recently other groups 
have shown that following treatment with rhEPO in KIKO mice, while there were no significant 
results in brain tissue, the peptide was able to induce an increase in frataxin mRNA levels in 
hearth, not followed by changes in frataxin protein levels (Miller, Rai et al. 2017). Unfortunately, 
no one has ever examined in depth the molecular mechanisms underlying frataxin (protein or 
mRNA) increases after the treatment with these compounds. 
 
 Physical activity and Neurotrophic Factors 
Physical activity is known to play a fundamental role in maintaining a healthy organism, 
bolstering the cardiovascular, endocrine and immune systems while providing also positive 
effects and benefits on the nervous system of an individual, promoting for example survival and 
maturation of cells of dentate gyrus and contributing to hippocampal neurogenesis in adult rodent 
models (Kempermann, Brandon et al. 1998; van Praag, Shubert et al. 2005). Even in humans, 
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adults of over 60 years participating in regular moderate physical exercise protocols showed less 
risks of dementia and performed better in common memory tests (Colcombe and Kramer 2003; 
Kramer and Colcombe 2018) and, furthermore, exercise has been shown to have positive effects 
even on people affected by early stages of dementia (de Assis and de Almondes 2017). For these 
reasons, physical exercise is gaining constantly more importance even in neurodegenerative 
diseases since it could provide an effective strategy to prevent, or at least slow down, the 
deterioration of the nervous system. Much is known about the benefits of physical exercise and 
its relation to neurotrophic factors in hippocampus, while little endeavors have been done 
regarding cerebellum. Furthermore, nothing is known about any kind of link between physical 
activity and FRDA. As described previously, an important approach when dealing with FRDA is 
trying to understand the mechanisms behind frataxin expression regulation in order to increment 
the levels of frataxin from dangerous pathological amounts to physiological ones. Indeed, recent 
studies from our laboratory have shown that the gene delivery of neurotrophic factors, such as the 
Brain-derived neurotrophic factor (BDNF) or Neurotrophin 3 (NT-3), protect from the 
neurodegeneration induced by low levels of frataxin protein both in vivo and in vitro (Katsu-
Jimenez, Loria et al. 2016). 
Interestingly, it has been demonstrated by other groups that physical activity induces 
neuroprotective effects by increasing the expression of several trophic factors, mostly in the 
hippocampus [eg. BDNF (Marlatt, Potter et al. 2012), Nerve Growth Factor (NGF) (Ang, Wong 
et al. 2003), Insulin-like Growth Factor 1 (IGF-1) and Vascular Endothelial Growth Factor 
(VEGF) (Ding, Vaynman et al. 2006), Glial-cell Derived Neurotrophic Factor (GDNF) (Campos, 
Rocha et al. 2016)]. Some studies have shown that the effects of physical activity on BDNF 
expression are mediated by the PGC-1α protein, a transcriptional coactivator involved in 
mitochondrial biogenesis and energy metabolism through activation of PPARthat, in turn, 
leads to the activation of a series of transcription factors like the cAMP response element-binding 
(CREB) protein or the Nuclear Respiratory Factor proteins (NRF 1 and 2) (Wu, Puigserver et al. 
1999; Wrann, White et al. 2013). As mentioned before, previous studies have indicated a direct 
correlation between the levels of PGC-1α, PPAR-γ activation and Frataxin levels (Coppola, 
Marmolino et al. 2009). However, the effects of physical exercise on frataxin expression, and the 
feasibility of physical exercise, or its effects at the molecular level, as a therapeutic avenue to 







6. FRDA: Therapeutic approaches 
Unfortunately, there still is no effective cure for FRDA. Nonetheless, many researchers are 
trying their best to dissect every mechanism of the disease in order to intervene at different stages 
of the disease itself, as visible in this picture taken from a recent review (Zhang, Napierala et al. 
2019) (Fig. 4). 
 
 
As clearly visible in the picture, many groups tried to improve mitochondrial function or to 
compensate for frataxin low levels through the use of some drugs capable to modulate its 
expression or to stabilize the protein itself. 
One of the first approaches has been to use antioxidant compounds to ameliorate the 
symptoms observed in patients due to excessive oxidative damage (vitamin E or coenzyme Q10, 
Figure 4 - Diagram showing current situation in FRDA research taken from Zhang et al., 2019 
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along with various analogs) (Jauslin, Vertuani et al. 2007), but their therapeutic efficacy remains 
doubtful (Kearney, Orrell et al. 2016).  
Another possible strategy is focused on compounds chelating iron, since in FRDA iron is 
accumulating inside the mitochondria. For this reason, iron-chelating compounds able to enter 
mitochondria are the most interesting: one of the most studied is Deferiprone, which is also used 
in thalassemia treatment. The problem with Deferiprone is that leads to secondary effects which 
can be quite troubling, as pointed out by Dr. Nancy Olivieri whose data suggests that this drug 
can lead to progressive hepatic fibrosis (Brittenham, Nathan et al. 2003). Even in vitro this drug 
is controversial, since the results obtained vary depending on the cell type used and the 
concentration, leading to improvements in mitochondrial functions in one case (Kakhlon, 
Manning et al. 2008) or to impairments in aconitase activity and decreased cell proliferation in 
another one (Goncalves, Paupe et al. 2008). 
Other approaches have tried to improve the impaired mitochondrial function, and the 
consequent oxidative stress, due to frataxin deficiency by intervening at different cellular events: 
this is the case of Omaveloxone, a drug stabilizing the transcription factor NF-E2-related factor 2 
(NRF2), which is involved in the antioxidant defense response. Omaveloxone inhibits NRF2 
ubiquitination, thus keeping it active to counteract the oxidative stress provoked by frataxin low 
levels (Abeti, Baccaro et al. 2018). 
Other groups focused their efforts in trying to resolve the issue entirely, through gene therapy, 
thus replacing the faulty gene with a correct one (Fleming, Spinoulas et al. 2005; Lim, Palomo et 
al. 2007), being this one of the most promising approaches. Being FRDA a monogenic disease, 
the substitution of the gene containing the GAA expansion with a healthy one would rescue the 
phenotype of the disease (Gomez-Sebastian, Gimenez-Cassina et al. 2007; Lim, Palomo et al. 
2007; Perdomini, Belbellaa et al. 2014; Piguet, de Montigny et al. 2018). There are some issues 
with this kind of approach since, to deliver the gene, the main limitation is the vector for the 
delivery itself., since viral vectors could provoke safety issues. To overcome these issues, a 
promising new alternative is represented by the use of synthetic nanoparticles carrying frataxin 
mRNA. A recent in vivo study demonstrated that, after intrathecal injections of these synthetic 
nanoparticles, frataxin expression was detected massively in dorsal root ganglia (Nabhan, Wood 
et al. 2016). 
Other possible treatments aim to enhance FXN gene expression through the use of several 
compounds that overcome the transcriptional deficit due to heterochromatization. In this group, 
the Hystone Deacetylase (HDAC) inhibitors can be found. HDAC molecules are able to 
counteract the huge heterochromatization induced by the GAA expansion, as described earlier, 
by incrementing the acetylation of hystones, which in turn leads to the DNA being more 
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accessible by the polymerase, leading to an increment in Fxn levels. The most promising in this 
class of compounds is the N-phenyl-N'-(2-Aminophenyl) hexamethylenediamide (BML-210), 
which reverted frataxin gene silencing in primary lymphoblasts of FRDA patients (Herman, 
Jenssen et al. 2006). The drawback of these class of compounds is that there is no way to 
specifically direct them on Frataxin gene, so adverse epigenetic effects might occur. 
Some studies with recombinant human (rhu)-EPO compounds have pointed at an increment 
in frataxin protein levels without rising mRNA levels, thus suggesting a post-translational 
regulatory mechanism of EPO on frataxin (Acquaviva, Castaldo et al. 2008), with the mechanism 
itself being still not very clear yet. After EPO treatments, frataxin levels seem to be incremented 
for about 30% and oxidative stress seems to be reduced, but hematocrit problems incurred after 
the chronic treatment (Boesch, Sturm et al. 2008) and that is precisely why alternative versions 
of the EPO peptide are gaining interest, lacking the erythropoietic functions in order to avoid 
undesired effects: this is the case of the carbamylated form of erythropoietin (CEPO), which is 
unable to bind classical EPO receptor, thus having no erythropoietic effects, but still able to 
increment frataxin levels in FRDA patient primary lymphocytes (Sturm, Helminger et al. 2010). 
Recently, several studies have shown also the potential effect of trophic factors in the 
regulation of frataxin expression or in the prevention of the negative effects induced by frataxin 
deficiency, being this yet another therapeutic approach for the disease. Trophic factors have been 
shown either to upregulate frataxin levels in YG8R transgenic mice (Calatrava-Ferreras, Gonzalo-
Gobernado et al. 2016) and, in our group, that the neurodegeneration elicited by frataxin 
deficiency in a mouse model is significantly reduced when the mice were injected with a viral 
vector carrying the Brain-Derived Neurotrophic Factor (BDNF) gene (Katsu-Jimenez, Loria et al. 
2016). 
Another important molecule involved in the regulation of frataxin expression is the 
peroxisome proliferator-activated receptor gamma (PPARγ), which seems to be a new promising 
therapeutic approach for the disease. A study using an agonist of PPARγ, Azelaoyl PAF, has 
shown that the treatment with this agonist is responsible of the direct upregulation of frataxin 
protein levels and mRNA levels (Marmolino, Acquaviva et al. 2009) and it has been confirmed 
that both PPARγ and its coactivator PGC-1α are downregulated in FRDA (Coppola, Marmolino 
et al. 2009), thus opening the way for new avenues for FRDA treatment. 
All therapeutic approaches involve some safety concerns, either for the possible toxicity of 







In this work, we have focused on some aspects about the regulation of frataxin both in cell 
models and in vivo, with the specific aims of: 
 
1. Characterizing the extra mitochondrial Frataxin isoforms. 
 
2. Studying the effects of erythropoietic-derived synthetic peptides on Frataxin 
expression. 
 
3. Exploring the regulation of Frataxin expression in vivo in mouse cerebellum 




Materials and methods 
 
1. Cell Cultures 
Cell lines HEK 293T containing the SV40 Large T-antigen (derived from human embryonic 
kidney) and SHSY-5Y (derived from human neuroblastoma) and were cultivated in Dulbecco’s 
modified Eagle medium (DMEM, Table 1), supplemented with 10% Fetal Bovine Serum (FBS), 
2mM L-Glutamine and Streptomycin/Penicillin mix (100 µg/ml, 100 U/ml). All the cell cultures 
were maintained at 37º with 95% humidity, in an incubator and a list of all media and supplements 
used is provided in Table 1. 
 
1.1. Olfactory Mesenchymal stem cells 
Olfactory mesenchymal stem cells (OMSCs) were obtained from voluntary donors both 
affected with FRDA or healthy. Biopsies were performed at the “Gregorio Marañon” Hospital, 
following the described protocols (Lanza et al., 1993). All the donors signed an informed consent 
and procedures were approved by the ethics committee of the hospital. OMSCs were plated in 
plates previously treated with Matrigel for 30 minutes at RT, and then cultivated in DMEM/F12 
supplemented with GlutaMAX, Albumax I 0,5% (w/v), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 10mM, glucose 0,6% (w/v), non-essential Amino Acids 
(NEAA, L-Ala 44mM, L-Asn 45mM, L-Asp 40mM, L-Glu 40mM, L-Pro 30mM), 2% FBS, 1% 
N2 Supplement, Streptomycin/Penicillin mix (100 µg/ml, 100 U/ml). 8 ng/ml human-
recombinant Fibroblast Growth Factor 2 (hrFGF-2) and 50ng/ml Nerve Growth Factor (NGF) 
were added freshly each time cells were passaged.  
 
1.2. FRDA Fibroblasts 
Human fibroblasts taken from FRDA patients and healthy subjects (GM08402, GM01652, 
GM08399 known as Ctrl1, Ctrl2 and Ctrl3 in order and GM0478, GM03816, GM03665, called 
FRDA1, FRDA2 and FRDA3 respectively, were obtained from Coriell Repository) and cultured 
in DMEM containing 10% FBS, 0,1mM Non Essential Amino Acids (NEAA) and supplemented 
with hrFGF-2 10ng/ml and Epidermal Growth Factor (EGF) 10ng/ml following an established 





1.3. Primary cultures of mouse cortical neurons 
Cortical Neurons were obtained from C57BL/6J mouse fetuses at E17-18, following 
described protocols (Bartlett & Banker, 1984). The dissection was performed in complete Hank’s 
Balanced Salt Solution (HBSS), after which the resulting cortexes were washed three times in 
HBSS deprived of Ca and Mg cations. A 15’ digestion with HBSS Ca2+ Mg2+ -/- containing 
2,5mg/ml Trypsin and 1mg/ml pancreatic bovine DNAse I was then performed at 37º, mixing 
every 5’. After the digestion, an accurate serie of washes with HBSS Ca2+ Mg2+ -/- was carried 
out to remove traces of trypsin and DNAse. Then, through a mechanical resuspension with a glass 
Pasteur pipette narrowed with fire, the cortexes were broken apart and the resulting cell 
suspension was plated on plates previously treated with 500µg/ml poly-L-Lysine in Neurobasal 
medium supplemented with B27, GlutaMAX I and streptomycin/penicillin mix. Cells were 
maintained in this medium for at least 3 days before starting the experiments. 
 
2. SHSY-5Y differentiation 
Human neuroblastoma cells were differentiated in neuron-like cells following two different 
protocols, one already tested in our lab (Gimenez-Cassina, Lim et al. 2006) and one recently 
published (Chiocchetti, Haslinger et al. 2016), which allows for SHSY cells to reach a more 
“mature” neuron-like phenotype. 
 
2.1. New differentiation protocol 
Cells were plated in plated treated with Matrigel at the same density as for the old protocol 
and maintained for one day in DMEM 10% FBS. The next day the medium is changed for 
Neurobasal-A supplemented with GlutaMAX I, B27, 10µM Retinoic Acid, 20mM KCl, 2mM 
Bucladesine (dbcAMP), 50ng/ml BDNF. Cells are cultivated with this medium for 11 days and 
the medium is changed every 2 days, adding BDNF, dbcAMP and Retinoic acid freshly each time. 









During the development of this thesis, many compounds were used and tested at the 
concentrations and times indicated for each experiment. The compounds were always added 
dissolved in medium and a control with just the medium used with the drug was always 
maintained to avoid non-specific results. 
 
Table 2 – List of media and supplements used in cell culture 
Product Commercial Brand 
Albumax Invitrogen, Life Technologies 
B27 Invitrogen, Life Technologies 
BDNF Alomone Labs 
dbcAMP Sigma 
DMEM CBMSO Culture Service 
DMEM/F12 Gibco, Life Technologies 
DNAse I Roche 
EGF Sigma 
FBS Invitrogen, Life Technologies 
Glucose Sigma 
GlutaMAX Invitrogen, Life Technologies 
HBSS Ca2+ Mg2+ -/- Gibco, Life Technologies 
HBSS Ca2+ Mg2+ +/+ Gibco, Life Technologies 
HEPES CBMSO Culture Service 
hrFGF-2 PeproTech 
L-Glutamine CBMSO Culture Service 
Matrigel BD Biosciences 
NEAA CBMSO Culture Service 
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Neurobasal Gibco, Life Technologies 
NGF Sigma 
Retinoic Acid Sigma 




4. Animal models 
 
4.1. C57BL/6 and YG8r mice 
All the work with mice employed for the experiments has been done following strictly the 
current regulations established by the Bioethics committee of the Autonomous University of 
Madrid. Two strains have been used: wild type C57BL6/J and a contracted human FXN transgenic 
mouse model with murine Frataxin knockout called YG8r. The mice were maintained in the 
animal facility of the CBMSO with proper light/dark cycles of 12hours each and at a constant 
temperature of 20º C. Food and water have been administered freely to the animals while the 
experiments were conducted.  
For the in vivo assays, C57BL6/J mice were intraperitoneally injected with 500µl NaCl 0,9% 
with or without compounds. The injections have been performed by the animal facility staff with 
a 0,3mm needle. For the genotyping process of the YG8r mice, DNA was extracted from the tail 
of the animal following standard protocols and then a PCR has been performed to determine the 
genotype: for the Fxn-/- genotype, a common forward primer (P3: 5’-
TGTTTACCATGGCTGAGATCTC-3’) was used along a primer specific for the wild type allele 
(MOF: 5’-AACGTTACTCTTAGGGTCAG-3’) or one specific for the KO allele (P2-Neo: 5-
CGCCTCCCCTACCCGGTAGAATTC-3’), giving a PCR product of, respectively, 350bp and 
240bp, visualized in a 2% agarose gel in TAE buffer (containing Tris base, acetic acid and 
EDTA). The PCR reaction was set up with the GoTaq G2 Flexi DNA Polymerase (Promega) 
supplemented with 5% DMSO, 25mM MgCl2, 10mM dNTPs and 0,4uM of the primers. Reaction 
conditions are described in the following table. For the FXN knock-in two primers amplifying the 





Table 3 – Genotyping PCR conditions 
Temperature Time Process 
94º 2 minutes Activation 
94º 20 seconds Denaturation 35 cycles 
54º 20 seconds Annealing 35 cycles 
72º 20 seconds Elongation 35 cycles 
72º 7 minutes Final elongation 
 
Furthermore, for the mice to reach pathological levels of human frataxin expression, fxn allele 
needs to be in hemizygosity, so qPCRs were needed to determine copy number. Different 
concentrations of DNA (5ng and 10ng) were tested by qPCR using the following primers for 
frataxin and a housekeeping of our choice:  
• Fxn Forward:   5’-CCCCTGATTTGCTGTATGCT-3’ 
• Fxn Reverse:    5’-CTCAAGGTCTCCGGACTTG-3’ 
• GAPDH Forward:   5’-CCCCTGGCCAAGGTCATCCATG-3’ 
• GAPDH Reverse:   5’-CAGTGAGCTTCCCGTTCAGCTC-3’ 
The reaction was set up with the “Fast SYBR-Green Master Mix” (Applied Biosystem), 
containing both the enzyme and the fluorescent dye, using the ABI PRISM 7900HT Fast. The 
results were analyzed by measuring fluorescence given by the intercalating agent SYBR-green, 
which is directly proportional to the amount of product generated though the cycles. We used the 
following conditions: 
1. Stage 1   20’’, 95º C 
2. Stage 2    1’’, 95ºC – 20’’, 60º C (40 repeats) 
3. Stage 3  15’’, 95ºC – 15’’, 60ºC – 15’’, 95ºC 
 
Dissociation curves of the analyzed DNA samples were studied in order to prove that no no-
specific product was obtained. Cycle quantification numbers (Ct) were analyzed to determine 
frataxin allele copy number and, thus, the genotype of YG8r mice. 
 
 
4.2. Protocol to monitor physical exercise in mice 
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All the work regarding the impact of physical exercise in mouse cerebellum has been done 
on a C57BL6/J strain at the Department of Physiology and Pharmacology (FYFA) of Karolinska 
Institutet (Stockholm, Sweden). All studies were performed with approval from the regional 
animal ethics committee of Northern Stockholm, Sweden (granted to Dr. Jorge L. Ruas), 
according to institutional and European guidelines for animal handling and research. All efforts 
were made to minimize the number and suffering of used animals. The protocol lasted 8 weeks, 
where the mice were subjected to spontaneous physical activity being able to mount, at discretion, 
on a treadmill connected to a laptop measuring the meters corresponding to the amount of 
exercise, except those used as control, which were not provided with any treadmill in their cages. 
After eight weeks all mice were sacrificed, and the cerebella were extracted to proceed with 
further analysis. 
 
5. Plasmid obtention, Viral production and titration 
 
5.1. Obtention of plasmids encoding for FXN isoforms 
The plasmid containing the cDNA for human frataxin was a kind gift of Dr Alexander and 
Dr Fleming (Fleming, Spinoulas et al. 2005) and is the one referred as pLv-Frat (or pLv-IsoI). 
The plasmids encoding for the cDNA of the different isoforms of frataxin were obtained, during 
this work, from the backbone of the pLv-Frat. The original plasmids containing cDNA for the 
isoforms (PET-II and PET-III) were a kind gift from Dr Xia and Dr Li (Xia, Cao et al. 2012). 
Since the only difference between the isoforms is in the first exon, we decided to clone and 
substitute the first exon of Iso II and Iso III contained in the PET plasmids donated by Xia et al 
in the pLv Frat previously used in the lab. To achieve this, we cut pLv-Frat with XbaI and BclI, 
which removes the first exon leaving the rest of the plasmid intact. The band containing the DNA 
was cut from the gel and purified with the Qiagen QIAquick Gel Extraction Kit. PET-II and PET-
III were partially digested with XbaI and BclI since the cDNAs of isoforms contained a XbaI 
sequence inside that needed to be left intact. Bands corresponding to the first exon of Iso II and 
Iso III were purified with the same kit described before. We then proceeded with the ligation 
between inserts and vector, respecting the molar ratio between them to ensure a proper ligation 
process. The resulting products were sequenced and aligned to ensure that no errors were done 
during the whole process. An E. coli bacterial strain (Stbl3) were then transformed and the 
colonies were checked by through a Mini Kit (Wizard Plus SV Minipreps DNA Purification 




5.2. HIV-1 derived lentiviral vectors production 
Three plasmids were used in the lentiviral vector production (2nd generation): 
• Packaging plasmid pCMV dR8.74 (5 µg) containing the viral genes gag, rev, pol and 
tat mandatory for producing viral particles 
• Envelope plasmid pMD2.G (2 µg) containing the env gene needed to pseudotype viral 
vectors with VSV-G protein 
• Plasmid containing the gene of interest (5 µg), described in table 2 
 
Table 4 – Plasmids used in lentiviral packaging and diagram showing them 
Product Commercial Brand 
MISSION pLK0.1 shRNA37 Sigma 
pRRL hCMV/eGFP WPRE Naldini lab 
pLVFRAT (or pLV-IsoI) Fleming and Alexander 
pLV-IsoII This thesis 
pLV-IsoIII This thesis 
 
 
These plasmids were added 
to 293T cells cultivated in p100 
plates at 80% confluence along 
with the transfecting reagent, 
Lipotransfectin (Solmeglas), 
following manufacturer 
instructions. After 48 h post 
transfection, the supernatant was 
taken and filtered with a low-
binding 0.45 µm filter, aliquoted 






5.3. Titration and transduction of target cells 
Virus expressing the green fluorescent protein (GFP) were titrated by cytometry: 293T cells 
were plated in M6 plates (200.000/w) and then infected with different amount of virus. After 48 
h cells were suspended in a fix buffer (Phosphate Saline Buffer (PBS), 2% FBS, 1% 
paraformaldehyde (PFA) ) and analyzed at the cytometer (FACSCalibur), calculating the 
percentage of GFP positive cells in 10000 events in order to estimate the viral titration of the 
starting aliquot. Since the whole process was done in parallel for GFP or other genes of interest, 
we approximated that the titer obtained for GFP was the same as the other genes. To realize the 
experimental procedures, a multiplicity of infection (MOI) of 5-10 was used depending on cell 
type, with the general guidance that minimum of 70-80% of the cells had to be transfected. When 
appropriate, an extra control of the transduction was used to remove any non-specific effects. 
 
6. Analysis of Protein Extracts 
 
6.1. Western Blot 
Two different buffers were used considering the starting samples: cells or organs. Cells, after 
removing the medium and washing with ice cold PBS, were frozen at -80º for at least 24 h. 
Following this step, cells were lysed with a cell scraper on ice with a buffer containing: 
 
• HEPES 20 mM pH 7,4 
• Sodium Chloride (NaCl) 100 mM 
• Sodium Fluoride (NaF) 100 mM 
• Sodium Orthovanadate (NaVO4) 1 mM 
• EDTA pH8 5 mM 
• Triton X-100 1% 
• Okadaic acid 1 µM 
• Protease Inhibitor Cocktail (Roche, cOmplete) 
 
For tissue extracts, the buffer used was a RIPA containing: 
• Tris HCl 25mM pH 7,6 
• NaCl 150mM 
• NP-40 1% 
• Sodium Deoxycholate 1% 
• SDS 0,1% 




Protein concentration, in both cases, was determined through Bradford assay following 
manufacturer instructions (BioRad) and read at a wavelength of 630 nm. After quantifying protein 
concentration, samples were mixed with loading buffer containing sodium dodecyl sulfate (SDS), 
boiled for 5 minutes and separated through polyacrylamide gel electrophoresis run in 15% 
acrylamide-bis-acrylamide gels or in 4-12% bis-tris plus gels (Invitrogen). The 15% gels were 
run in a Tris-Glycine buffer containing 10% SDS, while for the 4-12% we used the commercial 
buffer suggested by the manufacturer (MES Buffer, Invitrogen). Proteins were transferred on a 
nitrocellulose membrane (iBlot 2 NC Stack, Invitrogen) through the use of iBlot2 transfer device 
and then blocked with a 5-10% milk powder solution dissolved in PBS-Tween 20 0,2%. Blocked 
membranes were incubated overnight with the primary antibody (described in Table 3, following 
the suggested dilutions indicated by the datasheets) diluted in blocking solution at the 
concentration recommended by the manufacturer; after the primary antibody incubation, 
membranes were washed 3 times for 5’ each with PBS-T and then incubated with the Horse 
Radish Peroxidase (HRP)-conjugated secondary antibody of the appropriated host for 1h at room 
temperature following manufacturer instructions (Southern BioTech). After this, membranes 
were washed 3 times for 5’ each with PBS and then incubated 1’ with an Enhanced 
ChemiLuminescence (ECL) solution. The data were analyzed either by a Kodak X-Omat 2000 
processor or by the biomolecular imager ImageQuant LAS 4000 Mini (GE Healthcare). The 
resulting densitometry data were normalized for a control antibody versus a housekeeping protein 
(β-actin, GAPDH, β-Tubulin) in order to reduce the variation derived from the difference between 
loaded samples. The following table contains a list of the antibodies used in this work. 
 
Table 5 - List of antibodies used in western blots 
Product Dilution Commercial Brand 
Aconitase 1 1:1000 Abcam (#ab126595) 
Aconitase 2 1:1000 Abcam (#ab71440) 
Frataxin 1:1000 Abcam (#ab110328) 
Frataxin 1:500 Merck (#ab15080) 
Frataxin (H-155) 1:1000 Santa Cruz (#sc-25820) 
GAPDH 1:2000 Abcam (#AB8245) 
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IscU1/2 (D-6) 1:500 Santa Cruz (#sc-373694) 
Lamin B1 (S-20) 1:1000 Santa Cruz (#sc-30264) 
NDUFS3 1:1000 Thermo Fisher (#PA5-29747) 
VDAC 1:1000 Abcam (#ab14734) 
β -Tubulin 1:5000 Sigma (#T4026) 
 
6.2. Cell Fractionation 
To separate different cellular compartments before analyze protein expression, a commercial 
kit available from MitoSciences was used (Cell Fractionation Kit Standard, #MS861, 
(Chattaragada, Riganti et al. 2018; Paredes, Sheldon et al. 2018). Cells were plated and grown 
until semi-confluence. Cells then were trypsinized and centrifuged along with their supernatant. 
The resulting pellet was resuspended in the buffer A provided with the kit to have cells at a 
concentration of 6,6x106 cells/ml. This volume of cells in buffer A was mixed with an identical 
volume of buffer B, containing a special detergent able to break cell membranes and then 
centrifuged at 10000g. The resulting supernatant contained the cytosolic fractions. The pellets 
were resuspended in buffer A to be then mixed with buffer C, containing another detergent and 
then centrifuged at 10000g again. The supernatants, containing the mitochondrial fractions, were 
isolated and the pellets, composed by the nuclear fractions, were resuspended in buffer A. The 
samples were then added 5x SDS-containing loading buffer and boiled at 100º for 5’.  
  
7. Immunocytochemistry 
Cells for immunocytochemistry analysis were cultivated on glass coverslips at the optimal 
density depending on cell type. These cells were subjected to a sequential 4% PFA in PBS fixation 
protocol or an ice-cold methanol fixation protocol lasting 15’ at room temperature (RT)for PFA 
or at -20º C for methanol. After this procedure, the cells were washed 3 times with PBS and 
blocked for 1h at RT with a PBS solution containing 1% Bovine Serum Albumin (BSA) and 0,1% 
Triton-X 100. After the blocking, cells were incubated with the primary antibody diluted in 
blocking solution at the concentration suggested by the datasheet for 2h at RT or, alternatively, 
O/N at 4ºC. After the primary antibody incubation, the coverslips were washed 3 times with PBS 
and then incubated with the secondary antibody (conjugated with Alexa-488, Alexa-555, Alexa-
647) for 1h at RT, in darkness, and then washed again 3 times with PBS and then incubated with 
the nuclear counterstain DAPI (4’, 6-Diamidine-2’-phenylindole dihydrochloride) at the 
51 
 
concentration of 1 µg/ml for 10’. After this, the coverslips were mounted with the aqueous-based 
mounting medium Fluoromount-G (Southern Biotech) and analyzed at the Zeiss Axiovert 200 or 
at the LSM710 confocal scanning microscopes. 
Table 6 - List of antibodies used in immunocytochemistry 
Product Dilution Commercial Brand 
Frataxin 1:200 Abcam (#ab110328) 
Frataxin (H-155) 1:200 Santa Cruz (#sc-25820) 
GFP 1:200 Roche 
p-53 1:100 BD Pharmingen (#556534) 
β-III Tubulin 1:500 Sigma (#T4026) 
 
 
8. Aconitase assays 
Aconitase activity was measured with two different methods, one qualitative (in-gel) and one 
more quantitative (microplate): 
 
8.1. In gel assay for Aconitase Enzyme Activity 
This assay allows to visualize directly in the gel aconitase activity. The protocol was adapted 
from a published one (Shulman, Belakhov et al. 2014). Cells were harvested from plate with a 
lysis buffer containing: 
• KCl 40 mM 
• Tris-HCl 25 mM pH 7,5 
• Triton X-100 1% 
• 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) 0,21 mM 
• Dithiothreitol (DTT) 1 mM 
• Sodium citrate 2 mM 
• MnCl2 0,6 mM 




After a brief centrifugation at 13.000 rpm for 5’ at 4º, the supernatant was used to quantify 
protein concentration by a Bradford assay. Once proteins were quantified, loading buffer 4x (Tris-
HCl 10 mM ph8, Glycerol 34,8%, Bromophenol blue 0,1%) was added. 
Samples were separated through an electrophoresis in native conditions at 4º in a 4-8% 
acrylamide gel prepared with borate buffer and sodium citrate. The electrophoresis was run at 4º 
at 170V for 2-2,5 h with a running buffer containing Tris-Glycine and sodium citrate 3,6 mM. 
Once the electrophoresis was over, the gel was incubated in a staining solution for 30-60 
minutes at 37º in darkness.  
The staining solution is made of: 
• Tris 100 mM 
• Nicotinamide adenine dinucleotide phosphate (NADP) 1 mM 
• Cis-Aconitate 2,5 mM 
• MgCl2 5 mM 
• 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT) 1,2 mM 
• Phenazine Methosulfate (PMS) 0,3 mM 
• IDH (Isocitrate Dehydrogenase) 5U/ml 
After the staining, the gel was washed with deionized water for 5min for approximately 3 
times and then bands were visualized and scanned. 
 
8.2. Microplate assay for Aconitase Enzyme Activity 
For this assay, the commercial kit Aconitase Activity Assay Kit #ab109712 available from 
Abcam was used (Kauppila, Bonekamp et al. 2018; Vannocci, Notario Manzano et al. 2018). This 
kit allows to determine the amount of total aconitase activity from tissue or cultured cells by 
monitoring the formation of cis-aconitate, proportional to aconitase activity. The protocol was 
adapted and scaled down for our OMSc cell type. Results are expressed as the variation of 
absorbance per minute measured at 240nm in fixed time interval, compared to control group. At 








9. Enzyme-linked Immunosorbent assay (ELISA) 
The levels of Frataxin, BDNF and NT-3 in different experiments were evaluated through 
commercial immunosorbent assay kits available from different providers. 
For our experiments, we used the #ab199078 and #ab176112 from Abcam (Kemp, Cerminara 
et al. 2017; Khdour, Bandyopadhyay et al. 2018) to measure frataxin levels in mouse and human, 
respectively; the #CYT306 (Merck) for BDNF and the #LS-F5159 (LS-Bio) for Neurotrophin 3. 
In each case, the protocol from the manufacturer was strictly followed. The procedure, in all cases, 
involved a M96 plate pre-coated with the antibody against the selected protein (frataxin, BDNF 
or NT-3) to which samples are added. After this, a mix of secondary antibodies conjugated to 
streptavidin-HRP. These are used for the oxidation of 3,3’, 5,5’ – tetramethylbenzidine (TMB), 
which product can be detected at a wavelength of 450 nm. The values for the samples were 
interpolated from a standard curve prepared with known concentrations of the sample protein 
(frataxin, BDNF, NT-3), depending on the kit used. 
 
10.  RT-PCR 
In order to search for gene expression changes, reverse transcription-polymerase chain 
reaction (rt-PCR) analysis were performed. First, RNA was isolated from tissue (cerebellum) 
using a Direct-zol RNA kit (Zymo Research) following manufacturer instructions. Yield and 
purity of the obtained RNA was measured through a Nanodrop spectrophotometer. The RNA (1 
µg in 20 µl) was reverse transcribed into cDNA (50 ng/µl final concentration) using the Maxima 
First Strand cDNA Synthesis Kit for rt-qPCR (Thermo Fisher Scientific). The qPCR was 
performed starting from 10 ng of cDNA with the Luminaris Color HiGreen qPCR Master Mix 
(Thermo Fisher) with 600 nM primers and using the PikoReal Real-Time PCR System (Thermo 
Fisher) with the following cycling conditions: 50ºC for 120s, 95ºC for 120s, 40 cycles of 95ºC 
for 15s + 55ºC for 60s and 60º for 30s. The expression ratio was calculated using the ∆∆CT method. 
To normalize data, β-Actin expression was used to obtain relative expression values with the 
comparative Ct method. Specificity of the PCR reaction was validated by melting curve analysis. 
For all the experiments, primers were designed to span from intron-exon boundaries. Results are 
expressed as fold-change between control and samples group. In the following table, a list of the 






Table 7 - List of primers used in RT-qPCR 
Primer Sequence 
Actin Forward 5’-AACTCCATCATGAAGTGTGACG-3’ 
Actin Reverse 5’-GATCCACATCTGCTGGAAGG-3’ 
BDNF Forward 5’-TGGCCCTGCGGAGGCTAAGT-3’ 
BDNF Reverse 5’-AGGGTGCTTCCGAGCCTTCCT-3’ 
CSF3 Forward 5’-AGTCCCTGGAGCAAGTGAGG-3’ 
CSF3 Reverse 5’-AGAGCCTGCAGGAGACCTTG-3’ 
Frataxin Forward 5’-CCTGGCCGAGTTCTTTGAAG-3’ 
Frataxin Reverse 5′- GCCAGATTTGCTTGTTTGG-3′ 
Interferon-γ Forward 5’-GCTTTGCAGCTCTTCCTCA-3’ 
Interferon-γ Reverse 5’-CTTTTGCCAGTTCCTCCAG-3’ 
Interleukin 6 Forward 5’-TAGCTACCTGGAGTACATGAACA-3’ 
Interleukin 6 Reverse 5’-TGGTCCTTAGCCACTCCTTCT-3’ 
MIP-1ɑ Forward 5’-AAGATTCCACGCCAATTCATC-3’ 
MIP-1ɑ Reverse 5’-CAGGCATTCAGTTCCAGGTCAGT-3’ 
Neurotrophin 3 Forward 5’-CCGGTGGTAGCCAATAGAACC-3’ 
Neurotrophin 3 Reverse 5’-GCTGAGGACTTGTCGGTCAC-3’ 
Sonic Hedgehog Reverse 5’-GGGACGTAAGTCCTTCACCA-3’ 








11. Cytokine Array 
To search for possible candidates in the study of the regulation of frataxin gene expression 
after physical exercise, we decided to perform two cytokine array tests, the Mouse Neuro 
Discovery Array and the Mouse Cytokine Array C1 (both from RayBiotech), able to detect 
simultaneously a wide range of 37 cytokines. The procedure consists in incubating 50-100 µg 
tissue protein extracts on a membrane pre-printed with antibodies directed versus the selected 
cytokines. All the incubations steps were done overnight at 4º with gentle shaking, as suggested 
by the protocol, to obtain a stronger signal. Results were analyzed with ImageQuant 8.1 (GE 
Healthcare) software and results are expressed as fold changes between groups. 
 
12. Cellular Bioenergetic analysis  
Mitochondrial respiration was analyzed through the SeaHorse XF24 Extracellular Flux 
Analyzer (Agilent) with a protocol adapted from Dr, Ribeiro and Dr. Giménez-Cassina (Ribeiro, 
Gimenez-Cassina et al. 2015), measuring the oxygen consumption rate (OCR) per minute in cell 
cultures subjected to different modulators of respiration: 0,5 µM oligomycin, 0,75 µM Carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) and 4µM antimycin A, for OMScs and 
FRDA fibroblasts, while for cortical neurons, FCCP 0,25 µM was used. OMScs were plated at a 
density of 2,5x104/well in 150 µl of CSC medium, while neurons were plated at a density of 
1,5x105 in 100 µl of NB-B27. For the experiments, the medium was changed to a special DMEM 
without Glucose, Pyruvate and sodium bicarbonate NaHCO3 to which the nutrients to be 
consumed in the assay are added: Pyruvate 1 mM and Glucose 5 mM. OCR values are used to 
calculate different parameters of mitochondrial respiration, including basal respiratory capacity, 
maximal respiratory capacity, store respiratory capacity, proton leak and ATP-coupled 
respiration. 
 
13. Statistical Analysis 
As described in the figures, data were represented as mean ± SEM of at least three 
independent experiments from independent samples. When it was not possible reproduce the 
experiment three times, data were represented as mean ± SD. For the statistical analysis, 
GraphPad™ program was used and the most appropriate statistical test was used with the most 
appropriate correction, always indicated in figure legends. Statistical significance obtained after 
the analysis performed by the program, was indicated for the results that obtained a p value 






1. Characterization of Extramitochondrial Frataxin Isoforms 
With the aim of characterizing the functional relevance of the novel extramitochondrial FXN 
isoforms described by Xia et al. (Xia, Cao et al. 2012), we built lentiviral (LV) vectors carrying 
the cDNA encoding for FXN I, II and III. As a cell model we used OMSCs derived from both 
healthy subjects (henceforth C3c) and FRDA patients (AF6) and frataxin levels were then 




1.1. Subcellular localization of Isoform I, II and III in OMSc patient cells 
To confirm Xia et al claims about the different cellular compartments in which isoforms are 
present, we decided to perform a subcellular fractionation in OMSc patient cells after having 
transduced them with the Lv-Iso I, Lv-Iso II and Lv-Iso III for 48h. Compartment markers were 
used in order to prove that they were separated properly. Lamin B1 as nuclear marker, ATP 
Synthase (Complex V) for mitochondria and β-Tubulin as the cytosolic one (Fig. 6).  
Due to the strong expression of frataxin obtained after lentiviral transduction with LV-Iso I, 
some frataxin contamination can be seen in the nuclear compartment of the picture in panel A, 
while no housekeeping contamination can be detected. 
 
Figure 5 - OMScs cellular model obtention and frataxin levels quantification. Frataxin levels in healthy and patient 
OMSCs with relative quantification after densitometric analysis, where patients possess ~30% of fxn when compared 




Thus, we were able to confirm the cytosolic localization for isoform II in OMSc patient cells, 
along with the difference in molecular weight when compared to canonical Isoform I; but we did 
not confirm that Iso III is present in nucleus, in contrast to the previous results from Xia et al. 
(Xia, Cao et al. 2012). To have a better understanding about isoforms localization, we decided to 
perform immunocytochemistry experiments in OMSc patient cells (Fig. 7).  
 
Figure 6 - Cellular Subfractionation of Olfactory Mesenchymal Stem Cells. Cells from FRDA patient were transduced 
for 48h before the fractionation was performed with the protocol described previously in this thesis. The transduction 
was performed either with the lentivirus carrying the sequence of canonical frataxin (Iso I), or the different isoforms 
Iso II and III All results are in comparison with the Untreated condition (Untr). A) OMSC patient cells in which nuclear 
and mitochondrial compartment are clearly separated. Frataxin Isoform I is detected in mitochondria and Isoform II 
and III are detected in cytosol. B) Western blot showing OMSC patient cells results just for isoform II and. Frataxin 





As the picture shows, canonical isoform I co-localizes clearly with the mitochondrial network 
of the cells, while isoform II show a cytosolic pattern. We did not detect isoform III in the nucleus 
of the cells, as described by Xia et al (Xia, Cao et al. 2012). For this reason, we decided to perform 
another immunocytochemistry experiment analyzing the samples at the confocal microscope, 
which allowed us to perform a “z-stack” in order to check for presence of Isoform III in different 
planes of the nucleus (Fig. 8 – A). Furthermore, in the chance that Isoform III was somehow 
exported out of the nucleus during the process, we decided to treat the cells with Leptomycin B 
100 nM (Fig. 8 – B). Leptomycin B allows to inhibit nuclear exporting by blocking Exportin 1, 
thus blocking the translocation of proteins from the nucleus to the cytoplasm (Kudo, Matsumori 
et al. 1999). 
Figure 7 - Immunocytochemistry of OMSC patient cells transduced with Lv enconding for Fxn Isoforms. Cells were 
stained against anti-frataxin H155 antibody (green), while mitochondria were stained with Mitotracker Red and DAPI 
(blue) was used to stain nuclei. A) Untransduced OMSc patient cells with very low endogenous frataxin levels (40x). 
B) OMSc patient cells transduced with canonical frataxin isoform I (100x). C) OMSc patient cells transduced with 




After treating cells with Leptomycin B, 
we can see that p53 (shown in red) present in 
the nucleus, while Isoform III is still present 
in the cytoplasm of the cells, meaning that it 
is not exported from the nucleus to the 
cytosol, but that it was never in it. To check 
if Isoform II could possibly be located in the 
nucleus before being translocated to cytosol, 
we decided to perform the same Leptomycin 
experiment after transducing cells with Lv-
Iso II (Fig. 9) 
 
The results from this experiment clearly 
clarify that isoform II is strictly cytosolic and it does not seem to be present in the nucleus. In 
view of the lack of confirmation of the nuclear localization of FXN III, as previously reported by 
Figure 8 - Immunocytochemestry in OMScs transduced with Iso III. A) Z-stack of cells stained against Frataxin 
(green), Mitotracker (red) and DAPI (blue). B) OMSCs transduced with Lv-IsoIII and treated with 100nm Leptomycin 
B. Cells stained against Frataxin (green), p53 (Red) and DAPI (blue) (40x). 
Figure 9 - OMScs patient cells transduced with Lv-IsoII 
treated with Leptomycin B. Stained against frataxin 
(green), p53 (red) and DAPI (blue) (63x). 
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Xia et al. (Xia, Cao et al. 2012), we decided to focus our work on the canonical mitochondrial 
FXN I and the cytosolic FXN II isoforms. 
 
1.2. Subcellular localization of isoforms I and II in primary cultures of mouse 
cortical neurons 
We wanted to check if what we observed in human OMSc patient cells was also valid in 
neurons, for this reason we performed a subcellular fractionation of mouse cortical neurons 
transduced with lentivectors carrying Iso I and Iso II, performing also an immunocytochemistry 
(Fig. 10 – A, B, C, D).  
 
Figure 10 - Isoform I and II in E16 cortical neurons. A) Subcellular fractionation of E16 neurons. β3 Tubulin was used 
as cytosolic marker and ATP synthase for mitochondria. Isoform I cytosolic contamination is present due to its high 
expression. B) Untreated cortical neurons stained against frataxin (green), β3-tubulin (red) and DAPI (blue) (40x).  
C) Cortical neurons transduced with Lv-Iso I (40x). D) Cortical neurons transduced with Lv-Iso II (40x). 
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The results show that the same conclusion can be drawn for cortical neurons. The presence 
of canonical frataxin in the cytosol in the western blot is due to the high fxn expression achieved 
after the transduction with the lentiviral vector, which allows for an easy contamination, even 
though we did not detect Complex V (CV) signal in the cytosolic compartment. Another possible 
interpretation is that this strong cytosolic signal could be due to an alternative processing of the 
overexpressed FXN I precursor to the mature form. 
 
1.3. Time-course of Isoform I/II transduction 
Once we confirmed the results described by Xia, at least for isoform II, we decided to study 
how isoforms are expressed in cells over time after lentiviral transduction. For that reason, we 
decided to check in both models of OMSCs, the healthy and patient ones, to determine the 
appropriate time for future experiments (Fig. 11 A-B). As showed in Fig. 5 in panel B, patient 
cells express endogenously low levels of frataxin protein, around ~20-30% of the levels expressed 
in healthy subject cells, which are the levels we consider to be pathologic since the cells come 
directly from patients. 
Figure 11 - Frataxin levels in OMSCs. A) Time-course after transduction with Lv-IsoI (left) and Lv-IsoII (right) in 
healthy OMScs. B) Time-course after transduction with Lv-IsoI (left) and Lv-IsoII (right) in patient OMScs.  
C) Relative quantification of Frataxin overexpression with Lv-IsoI (left) and Lv-IsoII (right) in healthy OMScs.  
D) Relative quantification of Frataxin overexpression with Lv-IsoI (left) and Lv-IsoII (right) in patient OMScs. 
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Based on the results of our time-courses, we decided to use 48 h as a final time point for our 
future experiments, where frataxin is able to reach, in the case of healthy OMSc cells, around 
200% of basal levels. 
 
1.4. Mitochondrial network analysis in patient cells overexpressing frataxin 
isoforms 
Since, as it has been described in the introduction, we know frataxin plays a crucial role in 
maintaining mitochondria proper homeostasis, we wanted to check if the expression of isoform I 
and II could affect the mitochondrial network of the cell, focusing on their structure, networks, 
branches and length of the branches. For this reason, we decided to transduce OMSc patient cells 
with Lv-IsoI and II and then stain mitochondria with mitotracker red (1 μM, 30’) (Fig. 12 A-B-
C).  
 
Figure 12 - Mitotracker-stained OMSc patient cells to be processed with MiNA. A) Untransduced untreated patient 
cells. B) Lv-IsoI transduced patient cells. C) Lv-IsoII transduced cells. D) MiNA plugin allows to convert the images 
to binary and then elaborates a skeleton which is further analyzed to provide the parameters that characterize 
mitochondrial network,  such as individual mitochondria number, networked mitochondria number, size of the 
networks, length of the branches and total mitochondrial footprint. Data were represented as mean ± SEM and were 
analyzed with a two-tailed Welch’s t test with an n=6. 
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We then took pictures of mitochondrial structures at the microscope and analyzed the data 
with the ImageJ plugin “Mitochondrial Network Analysis” (MiNA, (Valente, Maddalena et al. 
2017) that allows us to examine deeper the morphology of mitochondrial network, number of 
punctate individual mitochondria, number of mitochondria forming networked structures, span of 
the network formed by mitochondrial net, length of the branches obtained in network junction 
points, along with total mitochondrial footprint, indicating the total area in the image consumed 
by signal separated from background (Fig. 12 D). 
Transduction with Lv-IsoI, as could be predicted, greatly improves the number of isolated 
and networked mitochondria, while no changes can be seen in regard to network sizes or length 
of branches with Isoform I or II. Cytosolic isoform II, in the specific, does not seem to modify 
the mitochondrial network. 
 
1.5. Mitochondrial bioenergetic analysis in OMScs 
We also checked if the mitochondrial metabolism was also affected by the overexpression of 
FXN isoforms. For this reason, we investigated what was happening at the respiratory chain level 
through Seahorse assays. With this technique, we can see how the respiratory chain is working 
by measuring oxygen consumption rate, ATP production, respiratory capacity and membrane 
integrity, all at once, giving insight on any kind of disfunction impairing mitochondria. During 
the assay, we measure Oxygen Consumption Rate (OCR) expressed as pico moles per minute.  
We used several compounds that interfered with different components of the respiratory 
chain, to elicit specific reactions. After measuring the “basal” OCR levels, we added oligomycin, 
an inhibitor of the F0 subunit of ATP synthase, causing a fall in the OCR which is associated with 
ATP production. Then, we added FCCP which acts as an uncoupling agent, transporting hydrogen 
ions through mitochondrial membrane disrupting the inner membrane gradient and “enhancing” 
the electron transport chain (ETC). This causes a sudden increase in the OCR, which gives us an 
idea of the maximal respiratory capacity of the mitochondria. Lastly, we added Antimycin A that 
blocks complex III, shutting down completely the entire electron transport chain process, thus 









The difference between Maximal and ATP-coupled respiration values, represents the so 
called “Spare capacity”, responsible of avoiding ATP deficits in critical energetic-demanding 
situations. The difference between respiration levels when adding Oligomycin and Antimycin A 
indicates the so called “Proton Leak”: H+ ions escape through the inner membrane, representing 
inner membrane integrity. All the modulators were added at the concentration described in the 
previous section of this thesis. 
We started by plating 25.000 OMSc cells in 100 µl of CSC medium, comparing the 
bioenergetics of healthy and patient cells by Seahorse assay (Fig. 14). We observed a non-
significant tendency of the healthy cells to show increased ATP-coupled respiration levels when 
Figure 13 - Diagram showing the theorical principles behind Seahorse assay. The modulators Oligomycin, FCCP and 
Antimycin A are gradually added to alter the electron transport chain and to permit to measure several parameters 
useful to assess mitochondrial metabolism. 
Agilent® 
Figure 14 - Seahorse assay in OMSCs in untreated conditions. Patient cells show a little tendency to have diminished 
levels of ATP-Coupled respiration rates while showing an increase in proton leak. Left panel: OCR variation in the 
different time points. Right panel: normalization of the results obtained in the experiment. Data were represented as mean 
± SD and were analyzed with an unpaired two-tailed t test with n=3. 
67 
 
compared to patient cells, which are, in turn, characterized by a significant level of proton leak, 
suggesting that their mitochondrial membrane is somewhat more damaged than in healthy cells. 
 
We, then, analyzed separately C3c healthy cells and AF6 patient ones after transducing them 
with lentivectors carrying GFP, Iso I and Iso II (Fig.15 A-B). We did not detect any significant 
change for maximal respiratory capacity or for ATP-coupled respiration (data not shown), while 
we saw an increment in basal respiration rate in both cell types after transducing with the 
lentiviruses carrying Isoform I and II (Fig. 15, lower panels). The basal mitochondrial respiratory 
capacity is calculated by subtracting the non-mitochondrial respiration (when Antimycin A is 
added) to the OCR values obtained before the addiction of oligomycin.  
  
Figure 15 - Seahorse analysis in OMScs from healthy and patient subjects. After transducing separately cells with the 
lentiviral vectors carrying Isoform I, II and GFP. A) Results for healthy OMScs with normalized basal respiration shown 
below. B) Results for patient OMScs with normalized basal respiration shown below. Data were represented as mean ± 
SEM and were analyzed with a two-tailed Welch’s t test with n=3. 
68 
 
1.6. Mitochondrial bioenergetic analysis in FRDA Fibroblasts 
In addition to OMSCs, we also analyzed the mitochondrial bioenergetics in another cell type: 
fibroblasts, from FRDA patients and from healthy donors. We plated 25.000 cells for well of 
Seahorse plate in the same medium amount and cells were transduced with Lv-GFP, Iso I and Iso 
II and then the experiment was performed (Fig. 16). We compared two different patient cells 
versus a healthy (control) fibroblast line. 
 
Figure 16 - Seahorse assay in fibroblast isolated from FRDA patients and healthy control subjects. Patient cells 
transduced with frataxin isoforms seem to perform better on the assay, getting closer to the healthy cells OCR values. 
Data were represented as mean ± SEM and were analyzed with multiples two-tailed  t-tests with a n=3. 
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For these cells, there is a clear separation between the different populations: FRDA patient 
cells visibly show less-performing mitochondria, translating in lower OCR values than healthy 
ones. When transduced with frataxin isoforms, they seem to recover mitochondrial function, even 
though not at the levels of healthy cells, probably because the transduction of lentiviral vectors in 
fibroblast is not as efficient as in other cell types.  
Maximal respiratory capacity appears to recover especially when cells were transduced with 
Isoform I, thus showing that frataxin is involved in supervising and maintaining mitochondrial 
homeostasis. No changes were detected between the two cell lines with or without isoforms in 
regard to proton leak or basal respiration rate (data not shown). 
 
1.7. Frataxin mediated regulation of mitochondrial related proteins 
With the deduction that frataxin expression is able to somewhat rescue mitochondrial function 
and reestablishing a correct functioning of the ETC, we then wanted to check if the over-
expression of the different isoforms was related to the regulation of a series of proteins crucial for 
the correct homeostasis of the organelle.  
After transducing OMSC cells with the different isoforms, we examined the protein levels of 
several factors involved in mitochondrial metabolism, like the Iron-Sulfur Cluster assembly 
scaffold protein 1 (ISCU1), Voltage-Dependent Anion Channel (VDAC) proteins, mitochondrial 
Aconitase 2, cytosolic Aconitase 1 and NADH Dehydrogenase Ubiquinone Iron-Sulfur protein 3 
(NDUFS3).  
While we did not detect significant changes in ISCU1, NDUFS3 or Aconitase 2 levels (data 






1.8. Aconitase activity modulation by frataxin isoforms 
Being both aconitases a candidate for interactions with frataxin (Condo, Malisan et al. 2010), 
we checked whether the different isoforms of frataxin were modulating aconitase activity. We 
know that Isoform I is surely capable of upregulating both the mitochondrial and the cytosolic 
aconitase (Bulteau, O'Neill et al. 2004) which was also demonstrated through an in-gel aconitase 
activity assay (Fig. 18). 
 
For this reason, we checked what happened 
when cells were also transduced with the lentiviral 
vector carrying Isoform II through a more sensitive 
and accurate kit for measuring aconitase activity 
assay, checking optical density (OD) variation 
during a fixed time of 40 minutes, even though not 
able to distinguish between the two different 
aconitase isoforms (Fig. 19). 
  
 
Figure 17 - Expression of mitochondrial-related proteins after transduction with frataxin isoforms in healthy and 
affected OMScs. A) Aconitase 1 expression modulated by lentiviral vectors carrying GFP, Isoform I or II. B) VDAC 
expression modulated by lentiviral vectors carrying GFP Isoform I or II. Data were normalized versus the untreated 
healthy control and represented as mean ± SEM and were analyzed with multiplestwo-tailed t-tests with a n=3. 
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Apart from the results obtained with this protocol in OMScs (Fig. 19 A-B), since the protocol 
itself was incompatible with this cellular model and was, thus giving unreliable results, we 
decided to perform the experiments also in neuroblastoma SH-SY5Y cells, transduced, besides 
GFP, Isoform I and II, also with the lentiviral vector carrying the sequence for a short-hairpin 
RNA used to reduce frataxin level to ~30% of healthy cells, thus mimicking patient conditions 
(Fig. 19 C). Nevertheless, no significant reduction in aconitase activity levels was detected with 
the shRNA, due probably to the fact that in 48h (our standard transduction time identified with 
the time course indicated in figure 11) Fxn levels were not low enough (around ~ 35-40% of 
untreated cells, data not shown) to be reflected on aconitase activity. SH-SY5Y were easier to 
adapt to the assay, giving us an enormous advantage during these experiments. While we did not 
detect any significant change between Aconitase activity levels between untreated healthy versus 
patient OMS cells (data not shown), probably due to their adaptation to culture or the excessive 
enrichment of their medium, for all cell types the same conclusions can be achieved: that both 
isoform I and II are able to modulate positively aconitase activity. 
 
Figure 19 - Aconitase activity assay in different cell models. Results in OMScs and SH-SY5Y show the same 
conclusions, that both the overexpression of Isoform I and II can improve Aconitase activity. A) Aconitase activity 
assay in healthy OMScs. B) Aconitase assay in patient OMScs. C) Aconitase activity assay in proliferating 
neuroblastoma cells SH-SY5Y.  Data were represented as mean ± SEM and were analyzed with a two-tailed Welch’s t 
test with an n=3. 
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Since, as we mentioned previously, frataxin may be involved in protecting ISCs from 
oxidative damage (Bulteau, O'Neill et al. 2004), we checked whether, after exposing 
neuroblastoma SY5Y to oxidative stress (in this case induced by 2 h of 500 μM H2O2), isoform 
overexpression was able to rescue aconitase activity (Fig. 20). 
 
 
As shown in the figure, after exposing neuroblastoma SH-SY5Y cells to H2O2 we can see a 
significant decrease in aconitase activity, probably due  to  the impairing of ISCs proper structure. 
After overexpression of the FXN isoforms, the impaired activity induced by the oxidative damage 
is completely rescued to values even higher than the untreated control, thus confirming that both 









Figure 20 - Aconitase  activity assay in SH-SY5Y exposed to oxidative stress. Cells were exposed for 2h to 500μM 
H2O2 before performing the assay. Hydrogen Peroxide effectively reduces aconitase activity when compared to 
untreated cells, while the presence of isoforms seems to totally rescue the reduction induced by oxidative stress. 
Data were represented as mean ± SEM and were analyzed with a two-tailed Welch’s t test with an n=3. 
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2. Regulation of Frataxin expression by Erythropoietic-derived 
peptides 
As described previously, another focus of this work has been the study of frataxin expression 
levels in response to erythropoietic-derivative peptides, not binding to the classical EPO receptor, 
but able to bind to the alternative one, promoting cellular growth and stimulating cell metabolism 
(Brines and Cerami 2005; Siren, Fasshauer et al. 2009). The results obtained for this part are in 
collaboration with the Institute for Research in Biomedicine (IRB) located in Barcelona (Spain), 
with the group of Dr. Ernest Giralt. Based on what we said previously, we synthetized 4 different 
versions of EPO-like peptides based on the retro-enantiomeric version of HBSP (ARA-290), 
having their sequence reversed and each residue in its alternative chiral form: the biggest advance 
of this is that these peptides are not recognized by peptidase enzymes, since they are able to 
recognize and bind L-aminoacids. In some cases, the biological activity of the original peptide 
may be retained in the retro-enantiomeric form (Nguyen, He et al. 2006). 
We analyzed four different EPO-peptides, plus a scramble peptide, as described in the 
following table: 
 
Table 8 - Different EPO-derivatives used in this work. 
EPO Code Sample MW Purity 
HBSP qeqleralnss 1257,3 95.9 
EPO 1 H-ssnlarelqeq-NH2 1273,27 < 98 
EPO 2 AC-ssnlarelqeq-NH2 1316,62 < 98 
EPO 3 HOOC-(CH2)2-ssnlarelqeq-NH2 1373,44 < 98 
EPO 4 NH2-ssnlarelqeq-COOH 1274,36 98 
NC2 AC-NH-lsneaeqsrlq-COOH 1316,39 < 98 
 
 
2.1. In vitro effect of Epomimetic peptides on frataxin levels in primary 
cultures of cortical neurons 
At first, we decided to screen the different peptides in vitro in primary cultures of mouse 
neurons to gain insight on which one was the best candidate producing the strongest results in 
modulating frataxin expression.  
Previous work from this lab demonstrated that the modulation induced by erythropoietic-like 
peptides seems to be mediated by several candidates, like the Tyrosine Receptor Kinase B (TrkB), 
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receptor of BDNF, or Sonic Hedgehog (SHH) (Thesis Dr. Yurika Katsu). For this reason, when 
evaluating the difference potential of the peptides we used, we treated the cells also with specific 
inhibitors of one pathway or the other, to prove their involvement in frataxin upregulation 
mediated by EPOs. We used Cyclopamine (cpm) that blocks SHH pathway through its binding 
to the receptor Smoothened. In normal conditions, SHH proteins are able to bind and inhibit 
surface membrane proteins called Patched, which in turn normally inhibits Smoothened.  
Even if SHH levels rise in the cell, the presence of cpm binding to Smoothened blocks it 
from further proceed with the signaling cascade. The other inhibitor we used was K252a, an 
alkaloid able to block the signaling pathway of the Trk family receptors, thus blocking TrkB. In 
our assay, we wanted to check if the possible augment in frataxin levels after epomimetic 
treatment could be blocked by using either inhibitor (Fig. 22). Neurons were harvested from E16 
mouse cortex and plated at a density of 500.000/ml in NB-B27. Epomimetic peptides at 500 ng/ml 
and drugs were added daily at the concentration indicated in the picture. 
 
 
The increment in frataxin level that we can see with the different epomimetic peptides, seems 
to be reduced when treating cells in parallel with the inhibitors previously described, pointing to 
an involvement of those pathways we mentioned earlier. Based on the results obtained, we were 
able to detect a strong significant effect on frataxin expression exerted by both EPO1 and EPO2, 
reverted when using the inhibitors previously described, underlining that the increment in frataxin 
Figure 22 - Cortical neurons treated with different synthetic EPOs and drugs inhibiting the suspected mediators. Cells 
were cultivated for 5 days during which EPOs were added daily at 100nM along with the inhibitors Cpm (5uM) and 
K252a (50nM). The increment in frataxin levels obtained after EPOs treatment, appears to be hindered in conjunction 
with the drugs. Data were represented as mean ± SEM and were analyzed with multiples two-tailed t tests, with a n=5. 
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detected was due to the activation of SHH and Trkβ pathway. We decided to focus our attention 
on the so-called EPO2, since it was the peptide that produced the most significant effect between 
the two.  
As a very early preliminary result, we analyzed mRNA levels of frataxin and several 
hypothetic candidates involved in its upregulation after treating neurons with EPO2 or HBSP for 
five days. We performed a qRT-PCR in E16 cortical neurons using different concentration of 
peptides to check for amount specific modulation of frataxin and of several candidate mediators 
for its regulation (Fig. 23). 
 
Both peptides seem to exert an equal effect on frataxin mRNA levels, while they seem to act 
differently on the mediators we have analyzed, with EPO2 causing a stronger effect on the 
Figure 23 - qRT-PCR preliminary analysis of frataxin and its possible mediators in cortical neuron after EPO2/HBSP 
treatments. A) FXN mRNA levels in cortical neurons after five days EPO2/HBSP treatments. B) BDNF mRNA levels 
in cortical neurons after five days EPO2/HBSP treatment. C) NT-3 mRNA levels in cortical neurons after five days 
EPO2/HBSP treatments. D) SHH mRNA levels in cortical neurons after five days EPO2/HBSP treatments. Results 
were represented as ΔΔCt means ± SD, in two replicates coming from the same starting RNAs (n=1). 
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neurotrophic factors BDNF/NT-3 while HBSP seems to upregulate SHH. These results will be 
further examined in depth in the future. 
 
2.2. In vivo effect of EPO2 in C57BL6/J mouse brain 
We checked the effect of EPO2 on a wild type C57BL6/J mouse strain. For these 
experiments, we first analyzed different concentrations of peptide in order to establish the best 
parameters for our future experiments. Results with primary cultures of cortical neurons showed 
that 113 ng/ml HBSP was able to induce the same upregulation on frataxin levels as 500 ng/ml 
EPO. As Dr. Katsu performed her in vivo experiments with HBSP 33 μg/kg animal, we decided 
to maintain the proportion and use three different groups of four C57BL6/J mice that were then 
injected intraperitoneally daily for 5 days with either 200 μg/kg or 400 μg/kg of EPO2 and 0.9% 
NaCl as control (n=2). After the protocol, mice were sacrificed, and tissues were extracted to be 
further processed. We analyzed the expression of frataxin in total brain extracts of the different 
groups, as indicated below (Fig. 24) 
 
 
Taking into account the results from the experiment, we decided to use 400 μg/kg as the 
standard concentration for our future in vivo experiments.  
 
Figure 24 - Frataxin levels in C57BL6/J mouse brain after EPO2 treatment. Mice were injected daily for 5 days with  
two different EPO2 concentration to determine which one was more suitable for future experiments. Data were 
represented as mean ± SEM and were analyzed with an umpaired two-tailed t-test with n=4. 
77 
 
Once we established the optimal concentration to produce a modulation upon frataxin 
expression, we analyzed the effects of the EPO2 peptide versus the original HBSP analogue, 
described previously. Three groups of C57BL67/J mice were injected intraperitoneally daily for 
5 days either with 400 μg/kg EPO 2 or 33 μg/kg HBSP and 0.9% NaCl as control, maintaining 
the ratio described by Dr. Katsu integrated with our previous results from the in vivo experiments 
described earlier. After the protocol, mice were sacrificed, and tissues were isolated for analysis. 




The results indicated that both peptides are able to increment frataxin levels for about 30% in 
the brain of C57BL6/J wild type mice. Being FRDA a disease that affects the whole 
spinocerebellar system, we decided to investigate the effects of the peptides in the cerebellum, to 
have a more comprehensive overview of the treatments with EPO2.  
Cerebellar extracts were obtained and frataxin levels were evaluated with an ELISA Kit 
specific for murine frataxin, as described in the “Material and Methods” section (Fig. 26). 
 
Figure 25 - Frataxin expression in C57BL6/J brain after EPO2 or HBSP treatments. Mice were injected daily for 5 
days either with NaCl, EPO 2 or HBSP. Both treatments seem to produce a significant increment in frataxin levels in 
the cerebrum. Data were represented as mean ± SEM and were analyzed with an unpaired two-tailed t-test with n=3. 
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In cerebellum, both peptides provoked again an increment in frataxin levels, but unlike what 
we have seen in cerebrum, EPO 2 caused a significant stronger increase when compared to HBSP, 
while in brain the response induced on frataxin levels from both peptides was equivalent. 
 
  
Figure 26 - Frataxin modulation in C57BL6/J cerebellum after Epo 2/HBSP treatments. Mice were injected daily for 
5 days either with NaCl, EPO 2 or HBSP. Frataxin levels were analyzed with an ELISA kit. Both EPO 2 and HBSP 
seem to upregulate Frataxin significantly, with EPO 2 achieving a stronger upregulation. Data were represented as 
mean ± SEM and were analyzed with an unpaired two-tailed t-test with an n=3. 
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2.3. In vitro analysis of the effect of epomimetic peptides on frataxin levels in 
FRDA patient cells (OMScs and fibroblasts) 
In addition to the results we obtained in vivo in mice, we examined the potential effects of the 
peptides in an in vitro cellular model for frataxin deficiency. Thus, we tested EPO 2 on healthy 
and affected OMS cells. Cells were cultivated at a density of 106/ml in a 6-Multiwell plate and 
treated daily with either EPO 2 or HBSP, both at 1 μg/ml. After 5 days, total protein extracts were 
obtained and analyzed through an ELISA kit specific for human frataxin (Fig. 27) 
 
 
No significant effect can be seen in healthy OMS cells, while patient cells seem to responde 
to the treatment with both Epo 2 and HBSP peptides at the concentration used. We also analyzed 
peptide effects on our FRDA fibroblasts, where we did not detect changes in frataxin levels when 
using the concentration we used in OMScs (1 μg/ml, data not shown) and for this reason we 
increased the concentration of our chronic treatment to 5 μg/ml and 10 μg/ml. After five days, 
cells were scraped and total protein extracts were obtained and analyzed through Western blot 
(Fig. 28).  
While for healthy fibroblast we detected an increment in frataxin levels with both peptides 
used for about 25~30%, results obtained in patient fibroblasts need to be further explored, even 
though cells seemed to respond to the treatments. 
Figure 27 - Frataxin modulation in OMScs after Epo 2/HBSP treatments. Cells were treated daily for 5 days with 1 
μg/ml of Epo 2 or HBSP. Frataxin levels were analyzed with an ELISA kit. Data were represented as mean ± SD and 










Figure 28 - Frataxin levels analysis in FRDA fibroblasts after chronic treatment with EPO2/HBSP. Cells were treated 
daily for 5 days with 5 μg/ml or 10 μg/ml of Epo 2 or HBSP. Frataxin levels were analyzed through Western Blot. Data 
were represented as mean ± SE and were analyzed with multiples t-tests with a n=4. 
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3. Modulation of frataxin expression in vivo in mouse cerebellum 
in response to physical activity 
As we mentioned previously in the introduction, physical exercise is nowadays considered a 
potential new therapeutic approach for many neurodegenerative diseases. Since no direct study 
between physical activity and Friedreich’s Ataxia has never been performed, we decided to 
investigate the role of the exercise upon the modulation of frataxin expression in collaboration 
with the laboratory of Dr. Jorge L. Ruas (Karolinska Institute, Stockholm, Sweden). 
With this objective in mind, we used two different groups of C57BL6/J mice: one subjected 
to a spontaneous physical activity protocol, in which mice were able, on their own, to start running 
on a wheel positioned in their cages (n=8), and the other one without any kind of wheel, so forced 
to be sedentary (n=7). Wheels in cages were connected to a laptop constantly measuring the 
amount of spontaneous physical activity performed by the mice (expressed in meters/24h). 
This spontaneous physical activity protocol lasted for 8 weeks and allowed us to identify a 
difference in the running behavior of the animals, with some of them running more than others 
along the different weeks. We, then, classified the running mice in runners and high runners, 
being high runners the mice that ran for more than 4000 meters/24h (Fig. 29). This separation 
simply worked as an internal reference for the interpretation of the results. 
 
Once the protocol was over, we sacrificed the mice and isolated the cerebella of the animals 
to proceed with the analysis of frataxin levels. 
 
 
Figure 29 - Diagram showing the results of the last three weeks of the exercise protocol. Shown are the distances run 
by individual mice (1 to 9). The results are expressed as meters/24h. Mice are indicated with number from 1 to 9. In 
red, the so called high runners are highlighted, an arbitrary nomenclature to identify the mice that have been running 
more than 4000 meters/day at least in the last three weeks of the protocol. Data were represented as mean ± SD. 
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3.1. Analysis of Frataxin levels in mouse cerebellum after physical exercise 
After tissue extraction, we decided to analyze both protein and mRNA level to check for 
possible transcriptional and post-transcriptional effects of physical exercise on frataxin levels. 
Cerebella from both mouse groups, sedentary and runner, were processed and examined (Fig. 30). 
 
 
While a significant difference can be seen in 
frataxin protein levels, the same cannot be said about 
mRNA. In order to check for any “activity amount”-
related effects, we further analyzed the samples by 
splitting runner and high runner (Fig. 31). The results 
seem to indicate a direct correlation between physical 
activity amount and frataxin protein levels, being 
frataxin more upregulated in the mice that ran the 
most. These results indicate that spontaneous physical 
activity increase frataxin levels in the cerebellum of 
wild-type mice. 
 
Figure 30 - Analysis of Frataxin protein and mRNA levels in mouse cerebellum after physical exercise. A) ELISA 
assay results representing Frataxin protein levels in Sedentary versus Runner mice groups. B) RT-qPCR results showing 
Frataxin mRNA levels in sedentary versus runner mice groups. Data were represented as mean ± SEM and were 
analyzed with an unpaired two-tailed t-test with an n=3. 
Figure 31 - Frataxin protein levels in 
mouse cerebellum after physical exercise. 
ELISA results splitting Runner and High 
runner group. Data were represented as 
mean ± SEM and were analyzed with an 
unpaired two-tailed t-test with an n=3 
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3.2. Identification of possible frataxin-regulating factors after physical 
exercise 
Once we demonstrated that frataxin was upregulated in mouse cerebellum after spontaneous 
physical activity, we tried to analyze some putative mediators of this effect. Many factors have 
been studied in the literature, but most of the studies focused on assess the mechanisms in 
hippocampus, cerebrum or total brain tissue, not focusing specifically on cerebellum (Vaynman, 
Ying et al. 2004; Marlatt, Potter et al. 2012). For this reason, we analyzed the levels of factors we 
know to participate in frataxin expression regulation, based on previous work from our laboratory, 
like BDNF, SHH and NT-3 (Fig. 32). 
 
Figure 32 - Analysis of several mediators for frataxin upregulation after physical exercise. A) Real-time PCR 
amplification of NT-3 transcript of sedentary versus runner group. B) Real-time PCR amplification of SHH transcript 
of sedentary versus runner group. C) Real-time PCR amplification of BDNF transcript of sedentary versus runner 
group. D) ELISA results of BDNF levels between sedentary and runner group. No significant changes detected for 
BDNF at protein nor mRNA levels. The mRNA expression was quantified using the comparative Ct method and data 
were represented as mean ± SEM and were analyzed with an unpaired two-tailed t-test with an n=3. 
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As the picture clearly shows, both NT-3 and SHH appeared to be upregulated in the 
cerebellum of mice subjected to physical activity. When the analysis was performed for BDNF, 
we were unable to detect changes in protein levels or in mRNA, meaning that BDNF is not 
upregulated with this kind of physical activity, at least in the cerebellum and after the eight weeks 
of the protocol. 
Since the effects on physical exercise on the cerebellum are not well characterized, we 
performed a cytokine array to identify possible changes in a wide spectrum of signaling molecules 





Figure 33 - Cytokine array in sedentary versus runner mice. A) Representative antibody cytokine array (37 cytokines) 
from cerebellar extracts from Runner (left) versus Sedentary (right) groups. Rectangles indicate positive controls 
(green). B) Graph showing the quantification of the array representing the cytokine expression in Runner (green) 
presented in fold change in respect to Sedentary (black) group. 
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The result of the array showed that a high number of cytokines appeared to be upregulated, 
like the Macrophage Inflammatory Protein-1α (MIP-1α), the Transforming Growth Factor β 
(TGF-β), Stem Cell Factor (SCF), the Receptor for Advanced Glycation Endproducts (RAGE), 
the Vascular Endotelial Factor A (VEGF-A) and the Matrix MetalloProtease 2 and 3 (MMP2/3), 
which are known to participate in angiogenesis processes. On the other side, some cytokines 
seemed to be downregulated, like Fas Ligand (FasL) or Fractalkine. Being physical activity a 
process involving practically the whole organism, it appeared obvious to have such a strong 
response after exercise. We decided to point our attention on those cytokines which might be 
involved in regulation of frataxin expression, such as the Macrophage Inflammatory Protein-1α 




Even though differences saw in the results were not significative, a tendency of the runner 
group to express higher levels of IFNγ and MIP-1α mRNA can be sensed. More studies are needed 
in order to reach a final and stronger conclusion. 
  
Figure 34 - RT-qPCR validation of some of the cytokines upregulated in mouse cerebellum after physical exercise.  
A) Real-time PCR amplification of IFNγ transcripts in sedentary versus runner group. B) Real-time PCR amplification 
of the transcript of MIP-1α in sedentary versus runner group. The mRNA expression was quantified using the 
comparative Ct method and data were represented as mean ± SEM and were analyzed with an unpaired two-tailed t-test 





1. Characterization of mitochondrial and extra mitochondrial 
frataxin isoforms 
Friedreich’s Ataxia is a mainly neurodegenerative disease caused, by the deficiency of the 
frataxin protein. Recently, several groups have reported the existence of several frataxin isoforms, 
with functions still not fully characterized and explored (Campuzano, Montermini et al. 1996; 
Xia, Cao et al. 2012), which has been a strong focus of our research. Xia et al. first described the 
different subcellular localization of the so-called Isoform II and III. Other authors have also 
described extra-mitochondrial frataxin isoforms, for example in erythrocytes it has been described 
an isoform (called Isoform E) quite similar to our Isoform II (Guo, Wang et al. 2018), or the 
existence of a pool of cytosolic frataxin involved in protecting cells from oxidative damage has 
also been indicated (Condo, Ventura et al. 2006). All these results opened the way for more 
questions about the physiological relevance of all frataxin isoforms in FRDA patients and healthy 
subjects, which has been one of the objectives of this work. 
We focused our studies on the alternative isoforms described by Xia, mainly due to the author 
claims about Isoform II being enriched in cerebellum, being this one of the most affected tissues 
during disease development.  
In all of our cell models, we have confirmed the cytosolic localization of Isoform II both by 
subcellular fractionation followed by Western Blot, or directly at the microscope after staining 
cells with specific antibodies. In contrast, we have not observed the presence of Isoform III in the 
cell nucleus of any of our cell models. In order to check for nuclear translocation events that could 
have caused our inability to observe it in the nucleus, we set up an experiment using Leptomycin 
B, a molecule originating from Streptomyces bacteria, know to interact and block the nuclear 
exporting pathway in humans. Not even with this setup we were able to observe its nuclear 
localization which is in strong contrast with Xia’s assumptions (Xia, Cao et al. 2012). We also 
checked whether Isoform II would localize to the nucleus in its maturation process and then be 
exported to cytosol: we then repeated the Leptomycin B experiment after transducing cells with 
the lentiviral vector carrying Isoform II sequence. This time we determined that Isoform II is fully 
cytosolic being synthetized and eliciting its functions in this compartment. Based on these results 
and also following Xia’s statement about the different tissue distribution of both isoforms, we 
focused our attention on the cytosolic Isoform II, most abundant in cerebellum which represents 
one of the most affected tissue by Friedreich’s Ataxia. 
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Once Isoform II localization was fully established as cytosolic, the fact that only the over-
expression of mitochondrial Isoform I was able to improve mitochondrial development by 
incrementing the numbers of both individual mitochondria and networks, did not surprise us.  
Nonetheless, we were able to see an improvement with both isoforms in mitochondrial 
respiration function after the overexpression of both frataxin Isoform I and II through Seahorse 
assays: using our OMS cellular model we detected changes in basal respiration rate in both healthy 
and patient cells. This increment in basal respiration rate could indicate that OMS cells are able, 
when over expressing Isoform I or II, to use the metabolites we provided during the experiment 
(glucose and pyruvate) in a better way than untreated or GFP-transduced cells. In FRDA 
fibroblasts, which are clearly impaired in mitochondrial respiration when confronted with healthy 
fibroblasts, we saw a marked increment in maximal respiratory capacity from patient cells when 
transduced with Isoform I or II compared to untreated or GFP-transduced patient ones. This 
clearly indicated that both isoforms can rescue mitochondrial function in different manners: 
Isoform I by acting inside mitochondria, while cytosolic Isoform II from the outside. We do not 
know the molecular mechanisms behind the mitochondrial activity rescue or the basal respiration 
increment induced by Isoform II, but one hypothesis could be that the extra-mitochondrial isoform 
of frataxin could be involved in facilitating the influx of metabolites from the cytosol to the 
mitochondria through mechanisms which remain to be determined. 
 This, actually, opens the way to many questions: since there were no changes in the rest of 
respiratory parameters, it would be worth researching on how these metabolites are being used 
and for what. ATP/ADP ratios or redox state (by evaluating the nicotinamide adenine dinucleotide 
oxidized/reduced (NAD+/NADH) ratio) could be evalued, especially since we also know that 
frataxin is involved in preventing the formation of ROS (Gakh, Park et al. 2006), thus preventing 
DNA damage and the activation of Poly ADP-Ribose Polymerase (PARP). PARP activation itself 
consumes NAD+ and also impairs glycolysis through the inhibition of hexokinase (Andrabi, 
Umanah et al. 2014), thus reducing the levels of pyruvate available for oxidative phosphorylation 
in mitochondria.  
Furthermore, many authors have shown that frataxin deficiency induces DNA damage 
(Chamberlain, Cramp et al. 1981; Haugen, Di Prospero et al. 2010; Coppola, Burnett et al. 2011; 
Khonsari, Schneider et al. 2016), by actively repressing DNA-repair pathways and, as a secondary 
cause, by provoking the production of ROS. The most interesting fact is that many enzymes 
involved in DNA repair seem to possess Fe-S clusters which are key factors for their proper 
functioning (Fuss, Tsai et al. 2015; Nunez, Majumdar et al. 2018), meaning that frataxin cytosolic 
isoform could play a crucial role in regulating and stabilizing these Fe-S clusters during DNA 





Trying to elucidate these processes, we searched for hypothetical interaction partners that 
could participate in the events described so far. Based on the results obtained by Condó et al. 
(Condo, Malisan et al. 2010) that showed that their extra mitochondrial frataxin isoform was able 
to interact directly with the cytosolic aconitase Aco1, we checked if this would be true also for 
our Isoform II. In both healthy and patient OMS cellular models, we confirmed that over 
expression of Isoform II caused an increment in the levels of cytosolic aconitase. Aco1 levels 
were also increased after over expressing the canonical Isoform I of frataxin, underlying the 
existence of a feedback circuit between the mitochondrial and extra-mitochondrial frataxins. To 
further prove this hypothesis, we checked the levels of a specific mitochondrial protein like 
VDAC that we know to be directly modulated by mitochondrial frataxin isoform I (Jasoliya, 
McMackin et al. 2017). Interestingly, we saw that both isoforms are able to significantly 
increment VDAC levels, at least in healthy subject, while a tendency has been seen in patient 
OMScs. Since we know that the over expression of Isoform II is not altering the levels of Isoform 
I, as shown in figure 6, these increments in VDAC levels are specifically due to the presence of 
cytosolic frataxin, thus highlighting again the existence of some form of feedbacks between 
mitochondrial and extra-mitochondrial forms of frataxin, that could participate in tandem in the 
regulation of the homeostasis of cells, as it has been also pointed out by other groups (Condo, 
Ventura et al. 2006). 
Figure 35 - Diagram showing possible involvement of frataxin isoforms in ROS action mechanism. ROS cause DNA 
damage and activation of PARP, prevented by the activation of DNA repair mechanisms, possibly through Frataxin 
Isoform II action. PARP activation impairs hexokinase, thus inhibiting glycolysis, reducing pyruvate levels available 
for the tricarboxylic acid cycle and oxidative phosphorylation. 
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While it is true that many metabolic pathways crucial for cellular homeostasis take place 
within mitochondrial compartment, that hence is strictly regulated in regard to iron metabolism, 
the potential roles of cytosolic isoforms of proteins involved in the regulation of the 
formation/repair of Fe-S clusters is gradually gaining more interest, since cells require two 
different sets of machinery for cluster biogenesis: ISC mitochondrial and CIA cytosolic 
machinery. Frataxin is not the only protein involved in Fe-S clusters formation and regulation to 
express extra-mitochondrial isoforms.  
This is the case of the cysteine desulfurase NSF1 (Li, Tong et al. 2006), or of Nfu, a protein 
necessary for correct iron sulfur clusters assembly with the role of removing sulfur from free 
cysteines and transfer it to scaffold ISCU proteins. Alternative splicing events of NFU1 gene 
cause the generation of a different, cytosolic, isoform that is able to bind Fe-S clusters and protect 
them from oxidative damage (Tong, Jameson et al. 2003). Moreover, cytosolic Nfu has been 
shown capable to transfer Fe-S clusters to IRP1, converting it into the cytosolic Aco1 isoform of 
aconitase. Even more proteins involved in formation and regulation of Fe-S clusters possess 
similar characteristics: this is the case of the scaffold IscU proteins. Transcript analysis indicated 
that alternative splicing events of the gene produce two different isoforms of IscU proteins with 
different subcellular localization: IscU1 in cytosol and IscU2, localized in the mitochondria (Tong 
and Rouault 2000).  
Interestingly, the alternative splicing produces a change only in the N-terminal of the different 
IscU proteins, which indicates a difference in their 5’ mRNA end, which mirrors what happens 
between Frataxin Isoform I and II. Canonical Frataxin is already known to participate with its 
mitochondrial partners in iron metabolism and Fe-S cluster homeostasis, while cytosolic frataxin 
II could act accordingly outside of mitochondria with the cytosolic isoforms of the other 
components (Fig. 36), communicating in a circuit involving membrane transporters (for example 
members of the ATP-Binding Cassette (ABC) family): it would be interesting to prove this 
working hypothesis in the future with co-immunoprecipitation assays to check for Isoform II 
association with possible cytosolic Fe-S cluster assembly and repair partners.  
It is worth of notice that many proteins involved in Fe-S cluster biogenesis possess cytosolic 
and mitochondrial isoforms (Land and Rouault 1998) or are suspected to relocate (Soltys and 
Gupta 2000), which indicate that cells are able to direct their assembly in both compartments and, 
possibly, to vary their ratio according with changes in the metabolic condition of the cell itself: it 
91 
 
would be, thus, interesting to check for the expression pattern of the previous factors we 
mentioned after varying parameters of cellular homeostasis. 
 
 
Several findings have shown the existence of a cross-talk between cytosol and mitochondria 
regarding iron metabolism: using a conditional frataxin knockout mouse model, it has been shown 
that frataxin knockdown in cardiomyocytes led to an impairment in ISC biogenesis and heme 
synthesis, while increasing both Transferrin and Transferrin Receptor 1 (TRF1) expression and, 
thus, iron uptake in an emergency response. This iron was rapidly directed to the mitochondria 
leading to a cytosolic iron-depletion and a mitochondrial iron-overloading (Huang, Becker et al. 
2009) in the effort to compensate for ISC and heme deficiency induced by frataxin silencing. The 
activation of Transferrin was accompanied by an inhibition of Ferritin, responsible of iron storage 
in cytosol, and an activation of the Mitoferrin protein, involved in the iron transport towards 
mitochondria, and these processes are probably regulated by iron-sensing IRP1 (Monnier, Llorens 
et al. 2018). Similar conclusions were achieved also in FRDA lymphoblasts (Li, Besse et al. 
2008). In this view, mitochondrion and cytosol are able to send signals between them to keep the 
balance in iron metabolism, with frataxin isoforms being capable to mediate this cross-talk in 
their respective compartments. It would be interesting to integrate the results obtained by Huang 
Figure 36 - Diagram showing possible mechanisms behind Fe-S clusters regulation in different subcellular 
compartments. Different isoforms of cysteine desulfurase NSF1 would transfer cysteine to their corresponding IscU, 
which would act with iron donated by the corresponding frataxin in order to regulate iron sulfur clusters formation in 
cytosol/mitochondria. In this view, both compartments could participate in iron sulfur cluster biogenesis thanks to 
transporters (ABC transporters) allowing transport of iron through the mitochondrial membrane. 
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et al. and by Li et al., by specifically silencing Frataxin cytosolic Isoform II, while leaving 
mitochondrial isoform I in its physiological levels, to analyze what would happen to iron 
metabolism in that case. Another interesting analysis that could give us more inside in this 
argument, and that we are currently starting to perform in our group, consists in isolating proteins 
from healthy and patient OMS cells and fibroblasts transduced with lentiviral vectors carrying 
frataxin Isoform I, II, GFP or left untreated. We would then perform a proteomic analysis of 
mitochondrial proteome after the transduction to check for broader effects of possible modulation 
induced in cells after the treatments. 
Apart from participating in Fe-S cluster biogenesis, frataxin may also act as a molecular 
chaperone to repair damaged [3Fe-4S] clusters in [4Fe-4S] one, by direct interaction with 
holoproteins that could contain a damaged cluster, like aconitase. As already described in the 
literature, one of the first causes of frataxin deficiency is shown in the decrease of mitochondrial 
aconitase activity (Rotig, de Lonlay et al. 1997) indicating an impairment in Fe-S cluster 
synthesis.  
On the contrary, we demonstrated that the over expression of mature frataxin can upregulate 
the activity of the enzyme in OMS patient cells, as shown in figure 18. Thus, we wondered if 
cytosolic isoform II could also possess the ability to modulate aconitase activity. Our Western 
Blot results pointed at a direct upregulation of Aconitase 2 levels directly dependent on the 
expression of Isoform I/II, while no apparent changes in Aconitase 1 levels were seen, probably 
due to imprecision of the polyclonal antibody we used that was not able to detect a clear band for 
the protein. On the other side, when evaluating aconitase enzyme activity, our results very clearly 
demonstrate that both mitochondrial Isoform I and cytosolic Isoform II are able to provoke a 
drastic increment in aconitase activity, which is a direct indicator that both isoforms are capable 
of improving the Fe-S cluster biogenesis and/or repair them from, and possibly in, their respective 
cellular compartments.  
Unfortunately, our protocol did not allow to distinguish between the different cytosolic or 
mitochondrial isoforms of aconitase and considered enzyme activity as a whole, but it would be 
of great interest to further confirm if Isoform I and II could specifically modulate the expression 
of a different isoform of the enzyme. Furthermore, apart from proving that frataxin isoforms 
incremented aconitase activity, we wanted to check if frataxin expression would be able to protect 
the Fe-S cluster of aconitase in oxidative stress conditions. For that reason, we decided to incubate 





Considering that our assay allowed to check for total aconitase activity, but also the fact that 
each isoform express itself in a different subcellular compartment, it is of great interest the fact 
that both mitochondrial isoform I and cytosolic isoform II resulted able to protect the Fe-S cluster 
of the different aconitase isoforms they interacted with. Aco1 and Aco2 could participate, 
alongside their corresponding frataxin isoform partner, in maintaining a regulatory loop between 
the mitochondrial and cytosolic reserves of NADP+/NADPH thanks to the conversion between 
Citrate - Isocitrate- α Ketoglutarate mediated by the different (mitochondrial and cytosolic) 
Isocitrate Dehydrogenase enzymes (Yoshimi, Futamura et al. 2016) (Fig. 37). 
 
The possible participation of Isocitrate Dehydrogenase 1 and 2 (IDH1 and IDH2) in the loss 
of the redox homeostasis upon frataxin deficiency is worth investigating in more detail. 
Interestingly, a relationship between IDH2, mitochondrial dysfunction and neurodegeneration has 
been indicated in some experimental models of Parkinson’s Disease (Kim, Kim et al. 2016; Yang, 








2. Frataxin regulation by non-erythropoietic EPO mimetic 
peptides 
As mentioned in the introduction, previous work demonstrated that EPO was able to 
increment frataxin levels in FRDA primary lymphoblasts, lymphocytes and fibroblasts (Sturm, 
Stupphann et al. 2005), while rising the hematocrit (Boesch, Sturm et al. 2008), making chronic 
treatments with canonical EPO unviable and that is why modified versions of EPO peptide are 
currently being used in research. Erythropoietin is a glycoproteic hormone mainly secreted by the 
kidney, with the prevalent role of inducing red blood cells production, inducing mitosis in 
erythroid precursors and secure survival of erythroid progenitors (Gross and Goldwasser 1970; 
Koury and Bondurant 1990). These effects are mediated after the binding to a homodimeric Epo 
receptor (EPO-R), which is located on the membrane of target cells, which after the binding gets 
glycosylated and phosphorylated (Sawyer and Hankins 1993). EPO-R belongs to the family of 
cytokine receptor whose signal transduction is mediated by Janus kinase (JAK). After EPO 
binding, EPO-R undergoes conformational changes that allow JAK kinases to associate with it, 
phosphorylating itself and EPO-R. This activates a signaling cascade resulting in the increase in 
the modulation, apart from erythropoietic genes, of survival, cell growth and anti-apoptotic factors 
mediated by the signal transducer and activator of transcription factors (STAT). EPO is not only 
involved in erythropoiesis and several other target cells and tissues have been identified over the 
years, including for example mouse cerebellum and cortex (Digicaylioglu, Bichet et al. 1995), 
where it has been shown that EPO expression can have neuroprotective effects after the induction 
of several stress conditions (Letourneur, Petit et al. 2013; Si, Wang et al. 2019) . This opened the 
way for the proposition of different pathways for EPO action: a classical erythropoietic one and 
the alternative promoting cell survival and growth ameliorating metabolically stressed tissues and 
cells. This secondary anti-inflammatory pathway is probably activated through the binding of 
EPO to an alternative EPO-R receptor composed by an heterodimer between classical EPO-R 
monomer and the receptor of several cytokines including interleukin 5 and 3 (Brines 2010). This 
alternative receptor is responsible for the cytoprotective properties of Epo (Brines, Patel et al. 
2008; Ueba, Brines et al. 2010). Some Epo-analogues like the carbamylated form CEPO or 
mimetic competitors like the small Helix-B Surface Peptide (HBSP or ARA290), can bind the 
alternative heterodimeric receptor without eliciting the effects of classical EPO. It has been found 
that HBSP, in mice, can protect cardiac functions and reduce apoptosis in cardiomyocytes after 
inducing ischemia (Liu, You et al. 2016)  and also attenuate cardiomyopathies after inducing 
diabetes (Lin, Zhang et al. 2017). The drawback of HBSP seems to be its low half-life that is 
around 2 minutes in plasma of rats and rabbits (Brines, Patel et al. 2008) and, for this reason, it 
appears fundamental to search for more stable alternatives, like the  retro-enantiomer peptides we 
focused on. After assaying various peptides with different chemical modifications in their N-
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terminal domain, we focused our efforts with the EPO2 that gave us the strongest response which 
could be due, for example, to stronger interactions with EPO receptor due to the acetyl group the 
peptide expressed. 
 In this work, we have demonstrated the effect of EPO2 on frataxin modulation, which has 
been confirmed both in vivo and in vitro in different models. In vitro, both peptides seemed to be 
able to produce an increment in frataxin levels, even though not as strong as the increments 
spotted in vivo. This could be due to the fact that both our cellular models, mesenchymal stem 
cells and fibroblasts, could express less EPO-R levels than the ones present in the whole target 
organ (cerebrum, cerebellum, etc.), thus eliciting a weaker response, or maybe for some instability 
of the peptides reacting with cellular medium components. Being able to see the effects of the 
peptides in in vivo brain extracts after being injected intraperitoneally, it seems safe to assume 
that EPO2 is capable of penetrating the blood-brain barrier (BBB) which is in line with what is 
known about classical human-recombinant EPO (Siren, Fratelli et al. 2001; Villa, Bigini et al. 
2003). Similar results on frataxin levels were seen in cerebellum extracts, where actually our 
EPO2 had a much stronger effect on frataxin when compared to HBSP peptide, which could be 
due to its stronger stability granting, thus, prolonged effects. Interestingly, other authors have 
used chemical agonists of alternative EPO-R (called STS-E412 and STS-E424) comparing them 
to rhEPO and have reported increased in vivo frataxin levels in their KIKO mouse model, but only 
in brain and heart (Miller, Rai et al. 2017). 
Previous work from our laboratory and other groups (Wang, Zhang et al. 2007) suggested 
that between the potential mediators of EPO (and its derivatives) effects are involved partners like 
SHH, which is why we used its inhibitor cyclopamine when screening between the four different 
synthetic EPO versions, the Signal Transducer and Activator of Transcription 5 (STAT5), 
mitogen-activated protein kinase (MAPK) or protein kinase C (PKC) (Hernandez, Burgos et al. 
2017; Suarez-Mendez, Tovilla-Zarate et al. 2018). Indeed, in order to search for possible 
mediators of the effects described, we performed, in cortical neurons, a qRT-PCR experiment 
where, as a very preliminary result, we saw a slight increase of some neurotrophins such as BDNF 
and NT-3 after the treatment with EPO2.  
Interestingly, other authors saw that, in cortical neurons, these neurotrophins, through the 
binding to their receptor of the Tyrosine Receptor Kinase family (Trk) are able to activate STAT5 
in a JAK-independent manner (Klein, Hempstead et al. 2005). Together this result with ours seem 
to indicate that EPO could activate STAT5 upregulating the expression of neurotrophins like 
BDNF or NT-3 that, in turn, could keep activating STAT5 in a paracrine or autocrine regulatory 
positive feedback. Furthermore, previous work from our lab has demonstrated that BDNF is 
directly related in the modulation of frataxin levels, so that could be another mechanism behind 
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EPO actions. Moreover, in our initial peptide screening, the frataxin upregulation observed after 
EPOs treatment was reduced when cells were treated with K252a, a specific inhibitor of protein 
kinase receptors of Trk family, target of neurotrophins (Tapley, Lamballe et al. 1992).  
Together these findings indicate that there is some correlation between these factors, EPO, 
BDNF, Trk receptors and SHH, whose regulatory mechanisms are still to be properly investigated 




Figure 38 - Diagram showing possible regulatory mechanisms behind frataxin modulation by EPO peptides. EPO 
binding to the heterodimer alternative EPO receptor activates JAK-STAT5 signaling pathway upregulating Sonic 
Hedgehog (SHH), Neurotrophin 3 (NT-3) and Brain Derived Neurotrophic Factor (BDNF). These partners are involved 
in frataxin modulation, since the use of SHH pathway inhibitor cyclopamine (cpm) or an inhibitor of the Tyrosine 
Kinase receptors (K252a) significantly reduces frataxin upregulation by EPO. Trk receptor activation by neurotrophins 
activates STAT5, thus hypothesizing the existence of a positive regulatory feedback circuit. 
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3. Physical exercise as a non-pharmacological approach for 
FRDA 
Finally, in the effort to elucidate novel molecular mechanisms behind frataxin regulation, we 
studied the effects of physical activity on the expression of frataxin in the cerebellum. 
Physical activity is a field constantly gathering extreme importance as a potential treatment 
for many neurological diseases, including Huntington disease (Busse, Quinn et al. 2013) and 
neuromuscular diseases (Cup, Pieterse et al. 2007). As previously stated in the introduction, 
physical exercise has been shown both in human and in mouse (Fordyce and Wehner 1993; 
Kramer, Hahn et al. 1999) to improve neural functions and to even be able to induce hippocampal 
neurogenesis (van Praag, Shubert et al. 2005), probably thanks to the positive effects of exercise 
on the production of several neurotrophic factors, cytokines and hormones. One of these possible 
mediators could be, for example, the Insulin-like Growth Factor-1 (IGF-1) which is known to be 
activated in brain after exercise (Cotman, Berchtold et al. 2007) and to exert positive effects on 
FRDA patients during therapies (Sanz-Gallego, Torres-Aleman et al. 2014). It is known that in 
hippocampus physical activity upregulates expression of factors like BDNF (Vaynman, Ying et 
al. 2004; Marlatt, Potter et al. 2012), through a pathway involving the activation of PGC1α and 
Fibronectin Type III Domain Containing 5 (FNDC5) (Wrann, White et al. 2013). The positive 
effects of moderate treadmill exercise were detected in mouse models of Alzheimer’s disease 
(AD), where PGC1α and FNDC5 upregulated BDNF levels preventing cognitive decline in these 
mice (Azimi, Gharakhanlou et al. 2018). Our lab has demonstrated the correlation between BDNF 
and frataxin (Katsu-Jimenez, Loria et al. 2016): that is why we wanted to investigate the effects 
of physical activity in the cerebellum on frataxin, being one of the most affected areas during 
FRDA development, as a potential non-pharmacological approach in FRDA treatment. In our 
experimental plan, we performed an eight weeks spontaneous physical activity protocol, during 
which the animals were free to run for the time and amount they desired, while we monitored the 
amount of physical activity expressed as meters/24h. Within this group, we were able to identify 
a subgroup of animals that ran more than other runners, which were useful to explore for 
regulatory effects directly dependent to the amount of exercise. We were able to see increments 
of frataxin protein levels in the runner group when comparing it to the sedentary one, with a 
stronger increment of frataxin levels in the high runner subgroup, pointing to an amount-related 
effect of spontaneous physical activity. Surprisingly, no frataxin mRNA changes were detected 
between the different groups, pointing the way for a post-transcriptional regulatory mechanism 
induced by spontaneous physical activity.  
Searching for mediators, we investigated whether there were changes in the factors we had 
already hypothesized to be involved in frataxin expression modulation. We saw increments in the 
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levels of NT-3 and SHH. SHH is also thought, in rat and mouse hippocampus, to be involved, 
with mechanisms not yet fully known, in adult neurogenesis, being activated after physical 
exercise (Banerjee, Rajendran et al. 2005; Fabel and Kempermann 2008).  
Surprisingly, we were not able to detect changes in BDNF levels, protein or mRNA, while it 
is well known to be upregulated after physical exercise in hippocampus (Vaynman, Ying et al. 
2004). This could be interpreted not as a lack of upregulation of BDNF but, as suggested by other 
authors, to the fact that this neurotrophin could be upregulated in the first time-window upon 
physical exercise, being transient and characteristic of the first “phase” (Klintsova, Dickson et al. 
2004). In their study, Klintsova et al. saw that, after a protocol of just two weeks of voluntary 
physical exercise (versus our eight), there were no changes in BDNF levels (mRNA or protein) 
in mouse cerebellum after the whole fourteen days period, while they were able to observe 
increments in BDNF levels during the first week of their experiment. So, BDNF could be an early 
mediator of physical exercise induced in the first phases, acting transiently to upregulate more 
downstream factors, like the previously mentioned NT-3 and SHH. To gain further insight on the 
possible mediators involved in frataxin increment post-exercise, we decided to upscale the 
screening with a Cytokine Array testing it with our cerebellar lysates, always comparing the 
sedentary and runner groups. We were able to identify several upregulated cytokines after 
physical exercise: between the highly upregulated ones, we found the Vascular Endothelial 
Growth Factor A (VEGF-A), which was expected, being a factor involved in promoting 
angiogenesis and vasculogenesis, events clearly promoted by any kind of physical activity 
(Morland, Andersson et al. 2017) and the Transforming Growth Factor β (TGF-β), which has 
been described to promote the “fatigue” sensation and to be upregulated by physical exercise 
(Inoue, Yamazaki et al. 1999).  
Besides, we identified several upregulated cytokines related to frataxin regulation and 
expression, which were the most interesting for our aims: MIP-1α, SCF, IFNγ and IL-6. 
Interleukin 6, considered to be a pro-inflammatory cytokine produced after several stimuli, was 
initially thought to be related only to the maturation of B-cells into antibody producing cell types, 
while later evidences demonstrated that it was expressed also in some neural cell lines (Yasukawa, 
Hirano et al. 1987), opening the way for its roles in axonal sprouting and regeneration in 
hippocampus (Hakkoum, Stoppini et al. 2007) and in adult neurogenesis (Bauer, Kerr et al. 2007), 
which is a phenomenon affected by a plethora of factors, including precisely physical exercise. 
In regards to MIP-1α and IFNγ, these two cytokines are known to be involved in inflammatory 
processes in the immune system, where secretion of MIP-1α from macrophages after recognition 
of pathogens, promotes IFNγ synthesis in Natural Killer (NK) cells (Schroder, Hertzog et al. 
2004) and there have been evidences of IFNγ release also by many cellular types of CNS, like 
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microglia, sensory neurons and astrocytes (Neumann, Schmidt et al. 1997; Lau and Yu 2001; 
Makela, Osterlund et al. 2011).  
Furthermore, MIP-1α receptors have been identified in several areas of CNS like 
hippocampus, cortex, cerebellum and brain stem (Van Der Meer, Goldberg et al. 2001; Xu, Long 
et al. 2009) and there have been evidences that, in rat hippocampus, chronic treatments with MIP-
1α improved neuronal activity by upregulating the N-methyl-D-aspartate receptor (NMDAR) and, 
consequently, Ca2+ signals, improving neuronal plasticity (Kuijpers, van Gassen et al. 2010). 
IFNγ, which is also involved in iron metabolism (Byrd and Horwitz 1993), has also shown 
promising effects in vitro in FRDA patient fibroblasts where it was able to increase frataxin 
mRNA levels (Wells, Seyer et al. 2015), and in vivo in YG8r mice, where, in dorsal root ganglia, 
IFNγ treatment resulted in improved coordination and locomotor activity (Tomassini, Arcuri et 
al. 2012). Finally, there have been evidences of IFNγ upregulating SHH mRNA and protein 
expression in cerebellum, showing a deep regulatory web between all the factors involved (Wang, 
Lin et al. 2004). Taken together into account, all these data seem to point to a deep regulatory 
mechanism started by physical activity that ultimately leads to frataxin upregulation, giving a 
stronger emphasis on exercise as a potential non-invasive treatment for FRDA (Fig. 39). It would 
be very interesting to investigate also the potential effect of a forced exercise, in a context of 
physical exhaustion, versus our voluntary running experiments to check which pathways are 
activated in that other model.  
In addition, as mentioned previously, one of the principal mediators of physical exercise 
effects is PGC-1α and, recently, it has been described that alternative promoters can be activated 
under different stimuli, resulting in the transcription of different PGC-1α isoforms, in particular 
the so called PGC-1α1 and PGC-1α4. The α4 isoform, after overexpression in skeletal muscle, 
seems to be involved in muscle hypertrophy, granting muscle mass and strength (Ruas, White et 
al. 2012), while isoform α1 seems to participate in oxidative metabolism and mitochondrial 
biogenesis, being responsible of improving endurance in muscle fibers (Arany 2008; Agudelo, 
Femenia et al. 2014).  
Under these interesting highlights, we are going to investigate the effects on frataxin 
regulation in transgenic mouse models constitutively expressing the different PGC-1α isoform in 
skeletal muscle, under the promotor of the muscle creatine kinase, which will further clarify the 
molecular mechanisms behind frataxin upregulation after physical exercise. Since we were able 
to obtain the samples just very recently, there has been no time to perform the appropriate 






Figure 39 - Model of frataxin regulation in cerebellum after spontaneous physical activity. Physical exercise, through 
a pathway involving PGC-1α, PPARγ and FNDC5, promotes the expressions of several neurotrophins and cytokines 
which are able to induce several positive effects on cells and, ultimately, to positively modulate frataxin levels. 
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4. Frataxin expression regulation mechanisms in FRDA  
There is no cure for Friedreich’s Ataxia, at the moment. Many therapeutic strategies are 
being currently investigated and explored, with some avenues being more promising than others. 
We have tried to elucidate some of the potential mechanisms behind frataxin expression by 
several factors which are getting more interest from a therapeutic point of view, like physical 
exercise or epomimetic peptides, showing that there is a direct effect of physical activity on 
frataxin levels involving many potential mediators that are also important in the epomimetic 
peptides response in our models, putting under the spotlight factors like neurotrophins, tyrosike 
kinase receptors and the Sonic Hedgehog signaling pathway (Fig. 40). Furthermore, we have also 
tried to enlighten the roles and functions on a controversial topic, like frataxin isoforms, which 
has been debated in FRDA literature without reaching clear conclusions on the potential roles of 
the different isoforms described. While we have not confirmed the existence of the nuclear 
isoform III, we have shown some of the potential cross-talk mechanisms between the 
mitochondrial Isoform I and the cytosolic Isoform II, which could prove useful in the unraveling 
of the molecular mechanisms during FRDA development. 
 
 
Figure 40 - Model of Frataxin regulation of the different approaches analyzed in this thesis. The model depicted in the 
figure illustrates the possible mechanisms behind frataxin regulation after physical activity or Epo mimetic peptides 
treatment. Physical exercise leads to the upregulation of the mediators of frataxin expression IFNg, NT-3 and BDNF 
and, consequently, to frataxin increased levels. Meanwhile, EPO2 binding to the heterodimer composed by EPO 
receptor and the alternative EPO-R, causes upregulation of neurotrophins like NT-3 and BDNF and activates the SHH 
pathway. In the presence of SHH, the cell-surface transmembrane protein Patched (PTCH) is inhibited, allowing the 
receptor Smoothenhead (SMO) to start its signaling cascade, ultimately leading to Frataxin increment. The cross-talk 





1. An extra mitochondrial pool of frataxin has been observed in several cellular 
models. The cytosolic localization of Frataxin Isoform II has been confirmed, 
while no nuclear Frataxin Isoform III has been detected. 
 
2. Frataxin Isoform I overexpression increase the mitochondrial network, while 
Isoform II overexpression does not have any observable effect in this aspect. 
 
3. The overexpression of both mitochondrial and cytosolic Frataxin isoforms 
improves mitochondrial respiration in FRDA patient cells and also increases the 
expression of some mitochondrial biomarkers (VDAC and aconitase). 
 
4. The overexpression of both mitochondrial and cytosolic Frataxin isoforms 
increases Aconitase activity, and furthermore protects the enzyme from oxidative 
stress inactivation. 
 
5. The retro-enantiomer erythropoietin-derived EPO2 peptide increases Frataxin 
expression in different cellular models and in vivo, in the cerebellum. 
 
6. Spontaneous physical activity in wild type mice leads to an increase in Frataxin 
levels in the cerebellum. This may be due at least in part to a post-transcriptional 
mechanism. 
 
7. Physical exercise in mice also increases the levels of some factors including 
SHH, NT-3, MIP-1α and IFN-γ, which might be putative mediators of the effects 
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